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Abstract
Background: Mental health recovery narratives have been defined as first-person lived experience accounts of
recovery from mental health problems which refer to events or actions over a period of time and which include
elements of adversity or struggle, and also self-defined strengths, successes or survival. They are readily available in
invariant recorded form, including text, audio or video. Previous studies have provided evidence that receiving
recorded recovery narratives can provide benefits to recipients.
This protocol describes three pragmatic trials that will be conducted by the Narrative Experiences Online (NEON)
study using the NEON Intervention, a web application that delivers recorded recovery narratives to its users. The
aim of the NEON Trial is to understand whether receiving online recorded recovery narratives through the NEON
Intervention benefits people with experience of psychosis. The aim of the NEON-O and NEON-C trials is to evaluate
the feasibility of conducting a definitive trial on the use of the NEON Intervention with people experiencing non-
psychosis mental health problems and those who care for others experiencing mental health problems respectively.
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Methods: The NEON Trial will recruit 683 participants with experience of psychosis. The NEON-O Trial will recruit at
least 100 participants with experience of non-psychosis mental health problems. The NEON-C Trial will recruit at
least 100 participants with experience of caring for others who have experienced mental health problems. In all
three trials, participants will be randomly allocated into one of two arms. Intervention arm participants will receive
treatment as usual plus immediate access to the NEON Intervention for 1 year. Control arm participants will receive
treatment as usual plus access to the NEON Intervention after 1 year. All participants will complete demographics
and outcome measures at baseline, 1 week, 12 weeks and 52 weeks. For the NEON Trial, the primary outcome
measure is the Manchester Short Assessment of Quality of Life at 52 weeks, and secondary outcome measures are
the CORE-10, Herth Hope Index, Mental Health Confidence Scale and Meaning in Life Questionnaire. A cost-
effectiveness analysis will be conducted using data collected through the EQ-5D-5 L and the Client Service Receipt
Inventory.
Discussion: NEON Trial analyses will establish both effectiveness and cost-effectiveness of the NEON Intervention
for people with experience of psychosis, and hence inform future clinical recommendations for this population.
Trial registration: All trials were prospectively registered with ISRCTN. NEON Trial: ISRCTN11152837. Registered on
13 August 2018. NEON-C Trial: ISRCTN76355273. Registered on 9 January 2020. NEON-O Trial: ISRCTN63197153.
Registered on 9 January 2020.
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Background
Mental health recovery narratives have been defined as
first-person lived experience accounts of recovery from
mental health problems which refer to events or actions
over a period of time and which include elements of ad-
versity or struggle, and also self-defined strengths, suc-
cesses or survival [1, 2]. They are referred to as recovery
narratives in this protocol whilst recognising that this
term is used elsewhere in healthcare research and prac-
tice, e.g. in narratives of recovery after a stroke [3]. Re-
covery narratives can be shared live, as part of social
interactions with others, or they can be presented in re-
corded form, as invariant text, audio or video [4]. In this
protocol, the person telling the story, in either form, is
referred to as the narrator, and the person reading,
watching, listening to or otherwise engaging with the
story is referred to as the recipient [5].
Sharing of recovery narratives is common [6, 7].
Informal peer support, involving interactions between
individuals with similar experiences of health problems,
is one example of a naturally occurring relationship in
which live recovery narratives can be narrated and
received. Informal peer support can take place in person
[8] or online [9]. In this century a new employment role
of peer support worker or peer specialist has emerged in
mental health systems internationally [10] which
involves employing people in roles for which personal
experience of mental health problems and recovery is a
requirement. Intentional peer support has an empirical
evidence base [11] and is being implemented globally
[12]. A US national survey has identified helping others
through the narrating of mental health recovery
narratives as a feature of the work of peer specialists
[13]. Peer support workers can create change through
mechanisms such as role modelling of individual
recovery [14]. Davidson et al. [15] have argued that the
disclosure by a peer worker of their own transition to a
“hero of their own self-journey” (p. 124) can instil hope
in others. The growth of peer support work means that
an increasing number of people living with mental
health problems have access to live recovery narratives
shared as part of a supportive relationship [15].
Access to recorded narratives is increasing [6, 7].
Substantial numbers of recorded recovery narratives are
publicly available, distributed through mechanisms
including books [16, 17], health service booklets [18],
online collections [19] and digital media hosting services
[20]. Creating narratives can also provide benefits for
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narrators [21], who might be motivated by sending
messages of “hope, courage and survival” (p. 68) [22], a
form of indirect emotional support [23]. Campaigns
which aim to reduce stigma [24, 25], such as Bell Let’s
Talk [26], have used recorded recovery narratives [27] as
a mechanism for creating social contact between people
with experience of mental health problems and others,
drawing on long-standing evidence for social contact as
an anti-stigma mechanism [28, 29]. Health material
shared in anti-stigma campaigns can have a beneficial
impact on help-seeking behaviour [30], a finding that is
important when systematic review evidence shows that
stigma can disrupt help-seeking behaviour [31]. Receiv-
ing a recovery narrative can provide personal inspiration
[32], increase empathy and understanding [33], validate
difficult personal experiences [34] or provide alternative
forms of companionship at times of social isolation [35].
Receiving recovery narratives can also contribute to re-
cipient distress, e.g. if the recipient feels angry or “out of
place” through a perception that he/she has experienced
greater hardship than a narrator [32].
The public availability of an increasing number of
recorded recovery narratives is an opportunity to
provide support to people through a new form of mental
health intervention. Organisations such as Here to Help
[36] and the Scottish Recovery Network [37] have
already created online collections of recovery narratives
with the explicit intent of supporting recovery in
recipients. These might be seen as a specific initiative
within a larger effort to incorporate digital healthcare
technologies (DHTs) into mental health practice,
motivated by known global challenges such as lengthy
waiting lists for treatment [38], limited access to in-
person mental health treatment in rural and remote
communities [39–41] and the distress inherent in acces-
sing in-person treatment for people experiencing social
anxiety [42]. Systematic review evidence shows that
DHTs can be effective at supporting self-management
for long-term conditions [43], and because face-to-face
contacts account for nearly 90% of healthcare interac-
tions [44], then developing self-management skills might
save health service resources as well as supporting better
long-term outcomes [45].
A recent qualitative study using semi-structured inter-
views to investigate the impact of receiving live and re-
corded mental health recovery narratives for 77
participants identified three benefits specifically attribut-
able to the supportive process of receiving recorded re-
covery narratives: obtaining access to narrators not
available in everyday life; having control over when and
how to access a narrative; and a lack of social interaction
burden around receiving the narrative [5]. The same
study presented a change model in which impact begins
with the recipient connecting to events in the narrative
or to characteristics of the narrator. Impact was reduced
if the recipient was experiencing a crisis, and was posi-
tively moderated by the perceived authenticity of the
narrative. Receiving recovery narratives created cognitive
and affective change in perceptions of connectedness,
validation, hope and optimism, empowerment, appreci-
ation, reference shift and reduction in self-stigma. The
definition of appreciation encompassed a subset of expe-
riences identified as “meaning in life” in a systematic re-
view on recovery processes [46]. Feeling empowered led
to helpful behavioural changes emulating those of the
narrator, such as increased likelihood of disclosure of
mental health experiences to others and greater ability
to exert control during interactions with mental health
workers. Harmful transdiagnostic forms of cognitive and
affective change can also be created by receiving recov-
ery narratives. These include perceptions of inadequacy,
disconnection, pessimism and burden. Interventions uti-
lising recovery narratives should consider how to man-
age and ameliorate harmful change [5].
A recent qualitative study [47] has refined the
mechanism of connection presented in [46]. It has
identified three factors underpinning connection:
comparison of self to narrator or narrative; feeling
empathy for the narrator; and learning something from
the narrative.
A recent systematic review [4] provides additional
specific items of knowledge that complement these two
qualitative studies, which post-date the review. It found
that recent traumatic events disrupt connection to a nar-
rator or narrative and hence reduce potential impact.
Receiving the recovery narratives of people experiencing
eating disorders can cause diagnostically specific harmful
behavioural responses in those with prior experience of
eating disorders, in the form of emulating harmful be-
haviours described by a narrator, especially if the
matched behaviours had been previously enacted by a
recipient. Emulation of narrator behaviours was initiated
by the elements of eating disorder recovery narratives
that described adversity or struggle. It was potentiated
by any specific detail about eating disorder behaviours
taking place during these periods, such as narrator esti-
mates of how many calories they were consuming.
The preceding evidence is primarily transdiagnostic,
since recovery is a multicomponent process which is not
diagnosis-specific [46]. However, there is specific evi-
dence that indicates possible benefits of recorded recov-
ery narratives in relation to people living with psychosis.
An Australian study identified benefits from recorded
recovery narratives in three domains: being inspired;
knowing I’m not alone; and believing recovery is possible
[34]. Recovery narratives can create hope, and messages
that create hope are known to be recovery-promoting in
psychosis [48]. Feeling more hopeful can also support
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recovery through re-imagining the self [49], and hope
mediates potential psychosis recovery indicators such as
increases in structured activity [50]. People experiencing
psychosis regularly use digital technologies such as social
networks [51]. Furthermore, a systematic review of inter-
ventions for psychosis incorporating online, social media
and mobile technologies concluded that these ap-
proaches are acceptable, feasible and have the potential
to improve outcome [52].
No prior randomised controlled trial (RCT) on the use
of recorded recovery narratives to provide benefits for
people experiencing psychosis has been conducted, and an
RCT would inform the development of diagnostically
specific clinical guidelines for the use of recovery
narratives with this population. We will conduct a
definitive pragmatic [53] RCT, the Narrative Experiences
Online (NEON) Trial, which incorporates an economic
and process evaluation. Recovery narratives and all trial
procedures (including randomisation) will be delivered
online through the NEON Intervention, a non-medical
online interface designed with the intent of supporting
people experiencing a wide range of mental health prob-
lems. The NEON Intervention provides a variety of mech-
anisms for accessing the NEON Collection of recovery
narratives. These include the use of a hybrid recom-
mender system [54], which uses both collaborative filter-
ing [55] and content-based filtering [56] to generate
automated recommendations of recovery narratives, tai-
lored to information collected about participants. The
content-based portion of the recommender system uses a
model trained using supervised machine learning [57] to
identify content that might provide benefits for a user.
In addition to people living with mental health
problems, recovery narratives may be relevant to their
informal carers, such as family members, friends,
neighbours and other unpaid supporters. Many carers
struggle with feeling pessimistic about the possibility of
recovery for their loved ones [58], and there is evidence
that being more “recovery-aware” gives informal carers
more hope and optimism about the future [59].
Established recovery frameworks are also relevant to the
experiences of informal carers, supporting processes
such as maintaining hope, reconnecting, overcoming
secondary trauma and (for family members) journeying
from carer to family [60]. Although the knowledge base
is less developed than for people with mental health
problems, current evidence suggests that recovery
narratives may also be beneficial to informal carers. As
such, we will use the same digital infrastructure to
conduct an exploratory study of the use of the NEON
Intervention for informal carers (the NEON-C Trial), to
inform the design of a future definitive RCT. Given the
transdiagnostic benefits of recovery narratives previously
identified, we will also run a second exploratory study
with people with non-psychosis mental health problems
(the NEON-O Trial).
Study aims and objectives
NEON Trial
The aim of the NEON Trial is to understand whether
receiving online recorded recovery narratives benefits
people with experience of psychosis.
The NEON Trial has primary and secondary
objectives.The primary objective is to evaluate the
effectiveness of the NEON Intervention in improving
quality of life at 1 year follow-up.
The primary hypothesis is that, compared to control
group participants not receiving the NEON Intervention
during that year, intervention group participants who
receive the NEON Intervention will have a clinically
important increase in quality of life 1 year later. Control
group participants will continue to receive usual care,
which has been described as the “comparator of choice”
(p. 92) [61] for pragmatic trials.
The secondary objectives are:
1. To evaluate effectiveness in improving hope,
empowerment and meaning in life and in reducing
symptomatology
2. To evaluate the cost-effectiveness of the interven-
tion compared with treatment as usual, from both a
health and social care provider and a societal
perspective
3. To understand how the intervention is used and
experienced
4. To evaluate the trial change model
5. To evaluate the performance of the supervised
machine learning algorithm in producing a model
that matches recovery narrative content to
participants
6. To understand how the model trained by the
machine learning algorithm develops through the
trial
7. To determine whether the effectiveness of the
NEON Intervention varies according to prior health
service usage by a participant.
The trial also has exploratory objectives:
1. To identify potential predictors of outcome, to
inform the design and analysis of future trials
2. To examine how the effect of the intervention
varies over time and by dose.
NEON-O and NEON-C trials
The aim of both exploratory trials (NEON-O and
NEON-C) is to develop knowledge to support the design
of a future definitive trial with the target population.
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The objectives are:
1. To optimise the intervention to the target
population, by using usage data to understand
patterns of dose and adherence, in order to identify
candidate refinements to the intervention
2. To optimise the evaluation to the target population,
including informing the choice of primary and
secondary outcome measures in a future trial
3. To establish trial parameters relating to the target
population, by evaluating recruitment procedures,
estimating recruitment rates and making a
preliminary estimate of effect size to inform a
future power calculation
4. To evaluate the performance of the supervised
machine learning algorithm in producing a model that
matches recovery narrative content to participants
5. To understand how the model trained by the
machine learning algorithm develops through the trial
6. To understand the acceptability of the intervention
to the target population.
The design decisions outlined in this protocol have
been optimised for the NEON Trial. Aspects of design
which differ in NEON-O and NEON-C are identified.
Study framework for evaluation
The Evidence Standards Framework for Digital Health
Technologies [62] has been used as a guiding framework
for evaluating the effectiveness of the NEON
Intervention. Within this framework, the NEON
Intervention is categorised as a tier 3a DHT, intended to
enable preventative behaviour change or allow self-
management of a diagnosed condition. A feasibility study
has provided observational evidence required for tier 3a
DHTs (Slade, Rennick-Egglestone, Llewellyn-Beardsley
et al: Using recorded mental health recovery narratives as
a resource for others: Narrative Experiences Online
(NEON) intervention development, submitted). All other
evidential requirements are covered by this trial protocol.
Study change model for the impact of recorded recovery
narratives
A change model has been synthesised from frameworks
developed in a systematic review [4] and qualitative study
[5]. The most empirically supported elements of these
frameworks were integrated, with priority given to those
which can be evaluated in a clinical trial with a process
evaluation. A specific focus was on the causal chain of
intermediate mechanisms between intervention and
outcome. The change model contains no diagnostically
specific elements and hence is appropriate for use in all
three trials described in this protocol. The change model
is presented in Fig. 1.
Initiation of help-seeking behaviours is included as a
helpful change, due to evidence that this can generally
be produced through exposure to mental health material
used in anti-stigma campaigns [30], although no evi-
dence as yet links initiation of help-seeking behaviours
to receiving recovery narratives specifically.
The change model includes emulation of harmful
behaviours as a general form of harmful change caused
by receiving recovery narratives. Whilst existing research
evidence for this is limited to recipients with prior
experience of eating disorders, receiving online material
featuring self-harm is known to have the capacity to po-
tentiate self-harm [63], and inclusion of a more general
formulation of harmful behavioural change in the
change model enables the selection of mechanisms to
manage it. As such, this inclusion is justifiable on the
biomedical principle of non-maleficence [64].
Methods
The NEON Trial is an RCT with an internal pilot and an
economic and process evaluation, and with all study
procedures other than process evaluation interviews
conducted online. The internal pilot sample will comprise
participants recruited during the first 3 months of the
trial, with trial recruiting continuing thereafter. NEON
Trial participants who meet the inclusion criteria will be
individually randomised into one of two treatment groups
(control group, intervention group) with an allocation
ratio of 1:1.
Follow-up is at 1 week, 12 weeks and 52 weeks after
randomisation, with the primary endpoint at 52weeks.
The cost-effectiveness of the NEON Intervention will be
established by calculating the costs of delivering the
NEON Intervention, the impact on services costs of re-
ceiving the intervention and the change in quality-adjusted
life years (QALYs) due to receiving the intervention.
The NEON-C and NEON-O exploratory trials are
RCTs with a limited process evaluation. Participants
who meet the inclusion criteria will be individually ran-
domised into one of two treatment groups (control
group, intervention group) with an allocation ratio of 1:
1. The same outcome data will be collected as for the
NEON Trial, at the same timepoints, but only explora-
tory clinical and economic analyses will be conducted.
As for the NEON Trial, all study procedures other than
process evaluation interviews are conducted online. Up
to 20 semi-structured interviews will be conducted for
the process evaluation in each of the NEON-C and
NEON-O trials.
Participants will not be blinded to allocation status in
any of the three NEON trials. There will be no
exclusions based on current treatment.
The schedule of enrolment activities, interventions and
assessments is shown in Fig. 2.
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Assessments at 1, 12 and 52 weeks are required for
clinical and economic analyses. The assessment at 104
weeks is not required, as only early recruits will reach this
before the study end date. Participation in interviews for
the internal pilot and process evaluation is optional and
not included in the figure.
Population
The study populations for the three trials are defined in
the following sections. All are self-rated, using a shared
online interface. Details are provided in the study pro-
cedure on Eligibility. No formal thresholds will be ap-
plied for language comprehension.
Participants will only be allowed to take part in one of
the trials. Where participants meet the inclusion criteria for
more than one trial, exclusion criteria have been included
to specify that the order of preference is NEON Trial
followed by NEON-O Trial followed by NEON-C Trial.
The NEON Trial
The inclusion criteria for the NEON Trial are as follows:
1. Experience of psychosis in the last 5 years
2. Experience of mental health-related distress in pre-
vious 6 months
3. Resident in England
4. Aged 18 or older
5. Capable of accessing or being supported to access
the Internet, either on a personal computer, mobile
device or at a community venue
6. Able to understand written and spoken English
7. Capable of providing online informed consent.
The NEON-O exploratory trial
The inclusion criteria are:
1. Experience of mental health problem other than
psychosis in the last 5 years
2. Experience of mental health-related distress in pre-
vious 6 months
3. Resident in England
4. Aged 18 or older
5. Capable of accessing or being supported to access
the Internet, either on a personal computer, mobile
device or at a community venue
6. Able to understand written and spoken English
7. Capable of providing online informed consent.
The exclusion criterion is:
1. Eligibility for the NEON Trial.
The NEON-C exploratory trial
The inclusion criteria are:
Fig. 1 NEON change model
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1. Experience of being an informal carer for someone
with experience of mental health problems within
the last 5 years
2. Resident in England
3. Aged 18 or older
4. Capable of accessing or being supported to access
the Internet, either on a personal computer, mobile
device or at a community venue
5. Able to understand written and spoken English
6. Capable of providing online informed consent.
The exclusion criteria are:
1. Eligibility for the NEON Trial
2. Eligibility for the NEON-O Trial.
Interventions
Control group
In all three trials, participants allocated to the control group
will have no changes to any treatment they may be receiving.
For the NEON Trial and NEON-O Trial, participants
will include:
1. People currently receiving no mental health
treatment
2. People receiving primary care mental health
treatment, such as pharmacotherapy from their
family doctor/general practitioner (GP) or
counselling from a primary care counsellor
3. People receiving support from the Improving
Access to Psychological Therapies (IAPT)
Fig. 2 Schedule of enrolment, interventions and assessments for all three trials
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programme, which provides evidence-based psycho-
logical therapies and routine outcome monitoring
to people living with common mental disorders
such as anxiety and depression, with an increasing
availability of services for people living with psych-
osis and other severe mental illnesses [65]
4. People receiving treatment from secondary mental
health services, such as locality-based mental health
teams or hospital-based services. In secondary care,
treatment typically involves multidisciplinary care
coordination under the Care Programme Approach
[66], a national framework for care coordination
and resource allocation in mental healthcare whose
key features include systematic arrangements for
assessing health and social needs; formation of a
care plan identifying the health and social care re-
quired from a variety of providers; appointment of a
key worker to monitor and coordinate care; and
regular review of the care plan.
For the NEON-C Trial, participants will not currently
be experiencing mental health problems, as otherwise
they would be eligible to participate in the NEON Trial
or NEON-O Trial.
Participants allocated to the control group in all three
trials will receive access to the NEON Intervention after
52 weeks, for at least 1 month or until the trial closes,
whichever is later. During this period, logging data will
be collected on their usage of the intervention.
Intervention group
For all three trials, participants randomised to the
intervention group will continue to receive their usual
care (if any). Typical offerings are as described for the
control group. The intervention group will also receive
immediate access to the NEON Intervention.
The NEON Intervention is a password-controlled, on-
line interface which presents mental health recovery nar-
ratives either sourced from existing public collections
such as books, health service booklets and online collec-
tions, or donated specifically to the NEON study by indi-
viduals. Narratives are managed in line with a protocol
previously approved by the Health Research Authority
(HRA) (Integrated Research Application System [IRAS]
247343, Research Ethics Committee [REC] reference 18/
LO/0991).
The NEON Intervention is accessed through a web
browser, either on a mobile phone or on a laptop or
desktop computer. It provides four routes to accessing
recovery narratives, which are described in the following
paragraphs, one of which uses an algorithm to match
narratives to participants. This is referred to as the
matching algorithm in the remainder of this protocol.
Information about participants used to generate matches
is referred to as matching data and is stored in a
personal profile along with other forms of personal
information needed by the NEON Intervention.
Information stored in the personal profile is detailed in
Additional file 1. All items in the personal profile are
considered to be research data. Titles or categories used
to display personal profile contents to participants may
be updated (for example, in response to feedback
collected through the internal pilot).
The NEON study Lived Experience Advisory Panel
(LEAP), consisting of 10 members with personal
experience of mental health problems, have advised that
participants should be able to provide as little or as
much information in their personal profile as they wish,
and hence we have minimised mandatory items in the
personal profile. Although there is some overlap with
the demographics form used by the NEON trials, the
contents of the personal profile are not auto-populated
from the demographics form. This maintains a separ-
ation between trial procedures and intervention usage.
The exception is contact details provided through the
consent form, which are essential for operation of the
NEON Intervention. Here, the personal profile will be
auto-populated to reduce participant burden.
After signing in to the NEON Intervention for the first
time, the participant is sequentially shown a number of
introductory pages intended to facilitate learning how to
work with the NEON Intervention, and to collect enough
information for the NEON Intervention to function
effectively. These pages will not appear on subsequent
logins. First interactions with a mental health technology
are known to present particular difficulties for users
experiencing mental health problems [67]; hence, these
pages have been designed to help a new user rapidly
acclimatise to the NEON Intervention.
The introductory pages appear in the following
sequence:
“Welcome” page This page provides a brief overview of
how to use the NEON Intervention; seeks to normalise
emotional responses to recovery narratives; and provides
initial guidance on how to deal with difficult emotional
responses.
“Initial information” page The Initial information page
allows the participant to provide an initial set of entries
for all “directly editable” items in their personal profile
(see Additional file 1). To support participants in
managing their own safety, this includes a list of types of
narrative content that they wish to hide, using a typology
of content warnings developed by the NEON study.
Some participants will be experiencing conditions that
disrupt processing of particular formats of narrative, e.g.
text-based narratives in the case of dyslexia. Some
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participants may have to use public computers to access
the NEON Intervention and hence may wish to avoid
formats of narrative that include audio. As such, users
can select formats of narrative that they do not wish to
receive. The NEON Intervention interface will not allow
users to block all formats, as then they would not be
able to receive any narratives.
The Initial information page will include text
indicating that personal profile contents can always be
updated through the “About Me” button during future
usage of the intervention.
“First story” page This provides a first experience of
receiving a short narrative, so that the user experiences
this as early as possible in usage of the intervention. A
short narrative will be displayed on this page. Only
narratives that do not have content warnings will be
considered in scope for selection so as to minimise
chances of distress. The selected narrative will not be of
a format blocked by the user, and hence some users will
receive different “first stories”.
After receiving this narrative, the participant will be
asked to rate it for hope, and optionally four types of
connection mechanisms. The following questions and
anchor points will be used, with indicated questions,
numbers and numerical ranges not visible to participants.
(Mandatory)
Q1: How hopeful did the story leave you feeling?
[range –1 to 2]
Less hopeful than before - No change - A bit more
hopeful - Much more hopeful
(Optional)
Q2: How similar was the story-teller to you? [range
0 to 3]
Not at all - A bit - Quite a lot - Very much
Q3: How similar was the story-teller’s life to your
life? [range 0 to 3]
Not at all - A bit - Quite a lot - Very much
Q4: How much did you learn from the story? [range
0 to 3]
Nothing - A bit - Quite a lot – A huge amount
Q5: How emotionally connected did you feel with
the story? [range 0 to 3]
Not at all - A bit - Quite a lot – A huge amount
Q2 and Q3 have been selected to operationalise the
connection mechanism referred to as “Self-to-other
comparison” in the trial change model (Fig. 1). Q4
operationalises the connection mechanism referred to as
“learning”. Q5 operationalises the connection mechanism
referred to as “empathy”. Responses to these five
questions are referred to as narrative feedback in the
remainder of this protocol, and will be used as matching
data. The NEON Intervention will encourage participants
to provide narrative feedback after each narrative received
through usage of the NEON Intervention, although it is
not technically possible to enforce this, since participants
can always close their web browser if they do not wish to
provide feedback.
The pool of narratives considered in scope for usage
as the first story will be reviewed approximately every 3
months after trial start. Drawing on all narrative
feedback provided by trial participants up to that point,
a small number of narratives will be selected which have
received hope ratings with a high mean and small
standard deviation (SD), as these are most likely to be
beneficial.
LEAP have advised that participants should be able to
block any story at any point (e.g. even partway through
reading or watching it), for example, if they found it
excessively distressing. LEAP have also advised that
recipients should be able to bookmark a story, e.g. to
allow an influential story to be re-visited or discussed
with a support worker. As such, buttons to block and
bookmark stories will be provided on the same screen as
the first story, and for all other subsequently accessed
stories.
After viewing the first story and providing narrative
feedback, the participant is given access to the
intervention home page. This presents four buttons in
an ordered list, allowing participants to access recovery
narratives in different ways:
 “Match me to a story (recommended)” button.
Requests the automated recommendation of
narratives matched to the participant, presented as a
list of stories. This will be the recommended approach
to narrative selection; hence, it appears first in the list.
The participant can choose to receive just one
narrative or can examine all in the list. The list will
only include narratives not seen before.
 “Get me a random story” button. Requests a
randomly selected narrative that the user has not
seen before, using an algorithmic pseudo-random
number generator.
 “Browse stories” button. Shows available narratives
grouped by tags, so that the participant can browse
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them. For example, the database may contain 245
narratives which relate to employment. The
participant can narrow the search by selecting
multiple tags, and can choose from narratives
matching selected tags.
 “My stories” button. Shows a list of recovery
narratives previously received, unless they have been
blocked, in which case they will not appear. They
are presented in two groups: (1) narratives
previously bookmarked by the participant, (2)
hopeful stories (those rated highest for hope, either
as indicated by the participant or by the cohort as a
whole). The participant can select a bookmarked or
hopeful narrative to be re-received.
The home page also contains a button labelled “About
Me”. Clicking this button opens a page allowing the
participant to update any information in their personal
profile marked as “directly editable” in Additional file 1.
It contains a link to a safety event reporting form, in
case the participant has experienced a serious adverse
event (SAE), and also a function to allow participants to
unblock all blocked narratives. Since even the titles of
narratives might be distressing in some circumstances,
this function will not display a list of all narratives that
have been blocked, and will instead just summarise the
number of blocked narratives.
To enable easy navigation, the footer of the NEON
Intervention, which is always available regardless of
which page is selected, will contain five buttons: Home,
Welcome, About NEON, I’m upset, Get me out of here.
Clicking these buttons causes the following actions:
 “Home” button. Takes the user straight to the
intervention home page.
 “Welcome” button. Displays information previously
provided on the “Welcome” and “Useful
Information” pages.
 “About NEON” button. Opens a page giving more
detailed information about the NEON Intervention,
including aims, how narratives were collected, how
to make best use of the intervention, information
about the funders, information about the study team
(including a link to the study website http://
researchintorecovery.com/neon), functionality to
view the consent form and functionality to initiate a
withdrawal from the trial.
 “I’m upset” button. Opens a page giving information
about dealing with difficult emotional responses.
This will remind participants of any self-
management strategies they have identified. It will
suggest common self-management strategies that
might help them. It will provide links to organisa-
tions and services that can be accessed by
participants, including charities and statutory health
services. The design of this page has been refined
with LEAP.
 “Get me out of here” button. Clicking this button
immediately closes the NEON Intervention web
page and logs the user out of the NEON
Intervention. It immediately takes the user to a
neutral web page (http://www.google.co.uk).
To distinguish the NEON Intervention from processes
associated with the trial (e.g. information sheets,
completion of measures), the NEON Intervention will
not be branded with study sponsor or research site
logos, and it will be presented with a contrasting colour
scheme. This is to support the ecological validity of the
evaluation by creating a visual boundary between trial
procedures and intervention content.
Participants can use the NEON Intervention as little
or as frequently as they wish, and there is no
expected pattern of usage. Patterns of usage will be
monitored algorithmically. If the participant has not
used the intervention for 1 month, then a reminder
message (which can be opted out of) will be sent
through contact mechanisms specified on the “About
Me” page. This will encourage the participant to re-
visit the intervention and give an option to access on-
line information about dealing with technical prob-
lems, such as reminders about the login procedure.
Messages may also be sent when new narratives that
might be of interest to participants are added, depend-
ing on the frequency of narratives being added to the
database.
Measures
All measures are included in Additional file 2. All
outcome measures to be used in the clinical outcomes
analysis are summarised in Table 1. The same measures
and timepoints will be used in all three trials. Responses
to items will be collected online, and validation rules
incorporated into online forms will ensure no missing
items.
The primary outcome measure used in all three
trials is quality of life, assessed with the Manchester
Short Assessment of Quality of Life (MANSA) [68] at
baseline and all follow-ups. MANSA has been success-
fully used to assess quality of life in individuals with
psychotic disorders [69, 70] and other forms of mental
health problem [71]. The score for MANSA is calcu-
lated from the 12 subjective items in Section 3 of the
measure [68].
Four clinical secondary outcome measures are used in
the three trials. The CORE-10 is a self-rated measure of
mental health distress, which includes 10 items relating
to depression, anxiety, trauma, functioning and risk to
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self [72]. The Herth Hope Index is a 12-item self-rated ab-
breviated version of the Herth Hope Scale [73]. The Mental
Health Confidence Scale is a self-rated measure of self-
efficacy amongst persons dealing with mental disorders
[74]. The Meaning in Life Questionnaire is a 10-item meas-
ure incorporating two subscales: presence of meaning in
life, anddegree of search for meaning in life [75]. All sec-
ondary outcome measures have been used successfully with
individuals experiencing psychotic disorders [65, 76–78].
Two measures are included for use in the health
economics analysis for the NEON Trial. The EQ-5D-5 L [79]
is a five-item self-completed measure of health-related qual-
ity of life which is used across a broad range of health condi-
tions. The Client Service Receipt Inventory (CSRI) is a
measure of service use that enables service costs to be esti-
mated and which can be tailored to each study’s require-
ments [80]. A version of the CSRI has been produced which
collects service use data covering primary care, secondary
mental and physical care, social care and time away from
usual activity/employment, defined using employment cat-
egories presented in the genetic mental health version of the
full CSRI [81]. These have been selected as the major cost
drivers of provision for the NEON Trial population. Item
count has been abridged relative to a typical item count for
the CSRI so as to limit the total burden on participants of
completing measures. CSRI completion at baseline will
have a 6-month retrospective period, and CSRI comple-
tion at 52 weeks will have a 12-month retrospective
period. The same data is collected in the NEON-O and
NEON-C trials. The health economics measures are sum-
marised in Table 2. Opportunistically, the same follow-up
data will be collected at 104 weeks for intervention group
participants who reach this timepoint, to allow for ex-
ploratory analysis of the longer-term impact of receiving
the intervention. Eligible participants will be those who
are randomised to the intervention group before end of
April 2020.
Power calculation
The NEON Trial is powered on mean item score for
MANSA. The primary endpoint for the NEON Trial is a
minimally clinically important difference in mean item
score. This is defined as an improvement of 1 scale point
in 3 out of 12 items at 1 year follow-up in the intervention
group relative to the control group. A total sample size of
683 (approximately 341 participants per arm) will provide
90% power to detect a minimally clinically important ef-
fect size (Cohen’s d) of 0.27, allowing for 20% attrition
(SD = 0.9 [82], power = 0.9, p = 0.05). This will give an
analysable sample of 546 (273 participants per arm).
The sample sizes for the NEON-C and NEON-O trials
have been chosen in order to calculate preliminary effect
size estimates to inform power calculations for future
trials. A total pilot study sample size of at least 70 has
been recommended to estimate the standard deviation
of a continuous outcome with good precision [83]. This
general rule has also been shown to be sufficient in
minimising the overall sample size across the pilot and
main trial when medium effect sizes are expected [84].
Allowing for 20% attrition, the target sample size for
both NEON-C and NEON -O will be at least 88 (44 per
arm). We have decided to use a conservative rounded-
up sample size of at least 100 (50 per arm) to reflect
possible uncertainty in the attrition level.
Procedures
Recruitment
The planned recruitment period for all three trials is 14
months. The mean recruitment rate for the NEON Trial
is 49 participants per month.
Table 1 Outcome measures used in the clinical outcomes analysis. “x” indicates a timepoint where measures are collected; bold text
indicates primary endpoint
Domain Measure Items Report Timepoint (week)
0 1 12 52
Quality of life Manchester Short Assessment of Quality of Life 12 Mean item score Range 1–7
Higher better
x x x x
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Effectiveness studies evaluate treatments in “real-
world” conditions [85]. An analysis of community survey
data from 18 countries found that mean lifetime
prevalence of ever having a psychotic episode was 5.8%
[86], whilst an epidemiological study conducted on a US
community sample estimated lifetime rates of psychosis
service usage in a range from 0.2% (narrowly defined
criteria) to 0.7% (broadly defined) [87]. Although these
studies cover different populations, we have assumed for
the purposes of recruitment planning that there is a
substantial population of people with experience of
psychosis but no engagement with statutory services.
Recruitment strategies for the NEON Trial will be
designed to target a purposive sample [88] of the target
population, with the sample containing a representative
spread of experiences of health service support for
psychosis experiences. Informed by the epidemiological
evidence, this will include participants who have
received no support from health services. The same
recruitment methods will be used for all three trials, but
recruitment effort will be prioritised to the NEON Trial,
which has the largest target sample size.
The following recruitment methods will be used to make
potential participants aware of the three NEON trials:
online advertising (disseminated on the study website, by
email and through social media networks); advertising in
print media; placement of posters and leaflets in health
service and community venues and in public places;
snowball recruitment; recommendation by general
practitioners, mental health workers and social workers to
clients (either in person or by other communication
mechanisms legitimately used by these practitioners); direct
approach by researchers to individuals who might be
interested in the study (either in person or by other
communication mechanisms legitimately used by
researchers to contact potential participants); presentations
by the study team; appearances of the study team in
national media; and recommendation by public figures with
an interest in mental health. Where individuals are to be
approached directly, governance of what is considered a
legitimate approach will be delegated to research sites. For
example, some research sites will have systems in place
which allow for the management of “consent to contact”
lists. These can be used to approach potential participants
in the three NEON trials if they are authorised for use for
these trials at the research site.
Where promotional material is used, it will vary
greatly in length and amount of information, e.g.
between text used in tweets and text used in posters.
We would anticipate sending out at least 100 pieces of
promotional material, each tailored to a different
audience and to the current state of the trial. Early on,
we may send out broadly relevant messages, and later
we may send out messages that are more targeted at
under-represented groups.
Principles to inform the text for all advertising are
given in Additional file 3. These principles allow for the
generation of recruitment material that is coherent and
ethically sound, but which can also be updated as our
understanding of how to promote the trial develops, for
example, in response to the analysis of the NEON Trial
internal pilot. All recruitment material generated will
conform to these principles. All promotional material
will be logged into the Trial Master File (TMF), with
date and location of use, to enable the study sponsor to
audit it against the advertising principles.
Sample recruitment posters are included in Additional
files 4, 5, 6 and 7. Their graphic design will be updated if
necessary, and new graphic designs will be submitted to
the HRA as a non-substantial amendment. Posters will
not be localised to research sites.
All recruitment activity will result in a participant
receiving the web address of the splash page for the
NEON trials. This is a publicly available online interface
which can be accessed from a public or private computer
or from a mobile device. The splash page incorporates a
link to a login screen for participants who have already
enrolled and have created an online account (“If you have
a login click here”). It will have a link to a trial
information page introducing the NEON Trial, NEON-O
Trial and NEON-C Trial. This will describe the purpose
of the trials and explain the process of enrolling, which
may not be familiar to some potential participants (“If you
are new to NEON click here”). It will link to a page to
allow people to report safety issues (see the section on
“Safety event monitoring procedures” for details).
The trial information page will indicate if any trial has
closed due to attaining the required participant count.
From the trial information page, a potential participant
can access an eligibility checking interface. The link to
the eligibility checking interface will be removed once all
trials have closed for recruitment, and all recruitment
Table 2 Health economics measures. “x” indicates a timepoint where measures are collected
Domain Measure Items Timepoint (week)
0 1 12 52
Health-related quality of life EQ-5D-5 L 5 x x
Service use Client Service Receipt Inventory (abridged). 6-month retrospective at baseline, 12 months
retrospective at primary endpoint
10 x x
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relating to that trial will be withdrawn as soon as
possible after trial closure.
Eligibility checking
To avoid the burden of an ineligible participant
engaging in informed consent procedures, potential
participants will be asked to answer a short series of
questions presented in an online interface. The primary
purpose of this interface is to establish eligibility for any
of the three NEON trials. The interface will also capture
how the potential participant learned about the NEON
trials so as to evaluate the effectiveness of different
recruitment methods. It will also capture sufficient
information to allocate the potential participant to a
research site if he/she is found to be eligible for a trial
and then choose to complete consent procedures.
For all three trials, the benefits of clinician rating of
eligibility are outweighed by the significant extra burden
on the participant, the likely lower recruitment rate that
would result (as some potential participants would not
wish their clinical team to be contacted) and the fact
that many potential participants will not be in contact
with mental health services.
The interface used to present online questions will be
publicly available. No online account is required to
access it. No personal data will be stored as a result of
interacting with it, as potential participants have not
given consent at this point in the study procedures.
Anonymous non-personal data will be stored to enable
accurate reporting of trial recruitment processes and to
inform advertising strategies. Before being presented
with questions, potential participants will be shown a
message, presented in text, which describes the purpose
of the chosen questions and which indicates that poten-
tial participants should only fill them out if they are in-
terested in taking part in one of the clinical trials.
Carefully crafted instructions can shape online experi-
ence and can support compliance with a designer’s
intended use for those experiences [89]. The current text
to be used is included in Additional file 8. If needed to
support effective use by participants, the text of all mes-
sages referenced in this protocol will be refined over
time, for example, based on feedback collected during
the internal pilot.
Eligibility checking and recruitment logging
questions Whilst all three trials remain open, questions
used to assess eligibility and log information about the
recruitment process are shown in Table 3.
Questions 3 through 8 in this table have been
discussed with LEAP, and the text of these questions has
been updated according to their recommendations.
Questions that relate to mental health have been
designed to be accessible to people who have never
received a formal diagnosis of any mental health
condition.
The flow of questions in the eligibility checking
interface will change as trials are closed for recruitment;
e.g. if the NEON-C trial had recruited all needed partici-
pants, then questions 7 and 8 would be removed. In that
circumstance, if a potential participant answered no to
all items in question 5, they would then be given a mes-
sage indicating they were ineligible for any trial.
Ability to engage with the eligibility checking interface
will be taken as evidence that the potential participant is
capable of using an online intervention, either supported
or unsupported. Items used in Q5 were drawn from the
Threshold Assessment Grid (TAG), a staff-rated meas-
ure of the severity of mental illness, for which validity
has been established [90]. The phrase used in Q6 for
verifying psychosis experiences in potential participants
has been developed from an earlier NEON study which
successfully recruited 28 participants with experience of
psychosis but no formal diagnosis [2, 5, 91].
If a potential participant has entered the eligibility
checking interface by clicking on a link in an online
advert displayed on a website, the identity of the website
displaying the advert will be logged automatically to
support an evaluation of recruitment methods, and Q1
and Q2 will be skipped. The potential participant will be
allocated to the Nottinghamshire Healthcare National
Health Service (NHS) Foundation Trust research site if
he/she chose to progress through informed consent
procedures, as all participants recruited through non-
NHS routes are recruited to this site. To enable this au-
tomated process, the web address presented in the on-
line advert will contain a parameter identifying the
online system which displayed the advert. As an ex-
ample, a web address including a parameter of 15 might
indicate an advert displayed on the website of the Uni-
versity of Nottingham.
Primary care recruitment for all trials is being
managed by primary care teams in the nationwide
network of Local Clinical Research Networks (LCRNs).
Q1 will enable a reasonable assessment of primary care
recruitment success, which will be considered in the
analysis of the internal pilot of the NEON Trial.
Secondary care recruitment for all trials is being
managed by selected mental health trusts in England,
who are operating as research sites. Q1 and Q2 together
will enable a reasonable allocation of a participant who
learned about the study through secondary care
recruitment. If “None of these” is selected for Q2, a
potential participant is allocated to the Nottinghamshire
Healthcare NHS Foundation Trust if the informed
consent procedures have been completed.
If responses to questions indicate that a potential
participant is not eligible for any trials, then once the
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questionnaire has been completed, he/she will be
informed of this, through a message designed to reduce
the number of people who experiment with responses so
as to obtain access to the NEON Intervention. The
current text is message 2 in Additional file 8.
If a potential participant is considered eligible for a
specific trial, then he/she will next move into informed
consent procedures.
Informed consent procedures
To ensure that a potential participant is sufficiently
informed to provide online consent for participation, an
online Participant Information Sheet (PIS) will be
provided to people considered eligible to participate in
any of the three trials. UK Health Research Authority
(HRA) guidance confirms that the online provision of
participant information is acceptable [92]. Items in the
PIS will be provided in a vertical list, through which
participants will be able to scroll up and down. At the
end of the PIS, a link will be provided to an Informed
Consent Form (ICF). The text/layout for the online PIS
is presented in Additional file 9; that for the online ICF
is presented in Additional file 10. The PIS will begin
with an invitation to take part in a named trial.
For some items, brief text with expandable detail has
been provided. This was recommended by LEAP, who
reviewed an earlier version of the PIS. It is consistent
with emerging evidence that shorter information sheets
are more likely to be fully read and more likely to be
understood [93], and it exploits the opportunity offered
by digital presentation to allow the potential participant
to manage how the relevant information is presented. It
also takes into account the intrinsically challenging and
potentially distressing nature of the first point of
interaction with a healthcare technology for a person
experiencing mental health problems [67], and is an
attempt to make this first contact as accessible as
possible. Navigation actions, such as scrolling up and
down or opening and closing further information, will
be logged anonymously to enable a quantitative
evaluation of PIS usage, and the use of expandable
details will be explored in the process evaluation. Data
collected anonymously will not be linked to the account
created for a participant who has completed all consent
procedures. The exception will be the research site to
which they should be allocated, which is inferred from
questions 1 and 2.
The PIS and ICF will contain contact details for the
NEON research team. Potential participants will be
encouraged to contact the team if they have any
questions not answered on the PIS. After reading the
PIS, a potential participant will be provided with two
buttons, labelled “I do wish to take part in the trial” and
“I do not wish to take part in the trial”. Participant
choice will be logged anonymously to allow for accurate
reporting of the trial. For participants who do not wish
to participate, this message will be displayed:
Thank you for considering involvement. If you
change your mind you are welcome to return and re-
register. You can safely close this window.
Participants who select the “I do wish to take part in
the trial” button will be asked to complete the online
Table 3 Online questions used to establish eligibility and log information about recruitment
Question Eligibility decision and next question
Q1: How did you find out about the NEON trials? [Through my family doctor or GP surgery, Through a
hospital or mental health service, Other]
Through a hospital or mental health
service: go to Q2
All other options: go to Q3
Q2: Was this through any of the following trusts? [List of current secondary care research sites, None of
these]
Go to Q3
Q3: Are you 18 or over today, and normally resident in England? [Yes/No] Yes: go to question Q4
No: not eligible for any trial
Q4: Can you understand written and spoken English? Yes: go to Q5
No: not eligible for any trial
Q5: Within the last 6 months, have you had mental health problems that:
a. Make it hard to manage the day-to-day demands of life? (No, A bit, Yes)
b. Currently cause you emotional distress? (No, A bit, Yes)
c. Cause you social problems like loneliness? (No, A bit, Yes)
No to all subquestions: go to Q7
Otherwise: go to Q6
Q6: In the last 5 years have you had experiences diagnosed as psychosis, or that you or others would call
psychosis (such as seeing or hearing things that others have not, or having unusual beliefs that other
people disagree with)? [Yes/No]
Yes: eligible for NEON Trial
No: eligible for the NEON-O trial
Q7: Within the last 5 years, have you cared for someone with experience of mental health problems? Yes: go to Q8
No: not eligible for any trial
Q8: Was this as part of your employment or profession? Yes: not eligible for any trial
No: eligible for the NEON-C trial
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consent form. A joint statement of the HRA and the
Medicines and Healthcare products Regulatory Agency
(MHRA) on seeking consent by electronic methods [94]
indicates that online consent is acceptable for all studies
other than Clinical Trials of Investigational Medicinal
Products (CTIMPs).
A key advantage of an online intervention is that
participants can use a system anonymously if they wish.
This feature is particularly relevant to the population for
the NEON Trial, since people with psychosis may be
particularly vulnerable to concerns about online data
usage and may also fear stigmatisation due to mental ill-
health [95]. There is evidence that the option to remain
anonymous influences decisions about use of online in-
terventions by people with psychosis [96]. The option to
remain anonymous has been successfully used in a num-
ber of online interventions with this population [97, 98].
Therefore, the person will only be required to check
each box on the consent form, rather than providing po-
tentially identifying information such as a signature. This
is in keeping with procedures specifically described and
allowed in [94]. However, as a minimum, potential par-
ticipants must provide a valid email address so as to en-
able the collection of online outcome data. Participants
who wish to remain anonymous can use email addresses
that do not include their name.
To consent to take part in the study, potential
participants must supply all mandatory information
required by the ICF, which includes providing a valid
email address. They are then provided with two buttons
labelled “I agree to take part in the study” or “I do not
wish to take part”. If they click “I agree to take part in
the study”, they will be given a message indicating that,
to complete the registration process, they need to click
on a link in a validation email sent to their account.
Since a working email address is required for usage of
the NEON Intervention, only potential participants who
click this link will be enrolled.
After clicking the link, the potential participant is now
enrolled in the study. Participants will be asked for a
password of their choosing, as it will then be easier to
remember. No password complexity rules will be
enforced. The participants will be reminded to make a
note of the login details and given the option of
receiving an automated email or text with the web
address and their login details. Although sending such a
message constitutes a potential security risk, this is a
population who may have cognitive processing and
strategic planning deficits. Therefore, the risk in this
case is outweighed by the benefits of offering the
participants the chance to have all information allowing
them to use the intervention in one place.
Participants will not be told of the research site to
which they have been allocated. This would be
confusing, as once an individual has confirmed
participation, all planned participant interactions are
either with the NEON Intervention or with the NEON
study team.
Baseline data collection
At first login, study participants in both groups will be
asked to complete baseline measures using an online
interface. They will be shown a message which explains
the purpose of completing baseline measures; provides
an estimate of how long the task will take; reminds them
that they can claim a voucher for completing it; and
reminds them that measures will need to be completed
again later in the trial. Some items in baseline measures
include questions that might be perceived as sensitive;
hence, the message recommends that the participant
should find a private place. The current text is message
4 in Additional file 8. Participants in NEON-O and
NEON-C will not be offered any payment for complet-
ing measures; hence, for these trials a modified message
will be used which excludes information about partici-
pant payment.
Participants will then be asked to complete a
demographics form and all measures. Each will be
presented on a single form, which will start with a title
and a single sentence describing the form, to support
participant comprehension of purpose. All critical
information to include on forms is summarised in
Additional file 2. Demographic items on English national
ethnicity [99] and on educational attainment [99] have
been simplified from those produced by the
Government Statistical Service guidance on harmonised
questions and concepts for social data sources. An item
on recovery status is included for those participants
experiencing mental health problems. This incorporates
a three-stage model of recovery, which currently has the
strongest empirical support [100], including through a
study which recruited in England [101].
To minimise data incompleteness, responses will be
validated as entered in the online forms used to collect
demographics and measures. For example, a participant
will not be able to click “Next” until all items on the
page have been rated, and can only provide an eligible
data value. If the web browser is closed before all items
are completed, then participants will be required to
continue completion at next logon. After submitting a
form, if a participant uses the “Back” button in the web
browser, then the form will be displayed again with all
data items entered automatically, and the participant
will be able to update the values that have been entered
and re-submit.
After completing the final form, participants will be
given a message thanking them for their responses and
confirming once again that their data is confidential.
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The back button will no longer take them back to a
previous form. NEON Trial participants will be provided
with a link to claim a £20 voucher as a compensation for
the time and effort of completing questions. The
voucher will be sent via the participant’s registered email
address, using an electronic voucher service provider.
Receiving a voucher is optional, and will always be
initiated by a participant. A request to be sent a voucher
will be logged for study reporting purposes.
In providing payment by voucher, there are two risks to
address. One risk is technical error in the implementation
of the NEON Intervention, which might result in multiple
vouchers being sent to a participant for a single set of
completed measures. The second is deliberate fraud, e.g.
through a participant registering multiple accounts purely
for the reason of claiming multiple vouchers. Thus, the
following management strategies have been selected:
1. The PIS will indicate that vouchers are paid up to 1
week after a claim is submitted, to allow the study
to team to investigate and verify unusual patterns of
voucher claims.
2. Each request for a voucher will require the approval of
an administrator, who will match the voucher request
to an available code. This means that no voucher
codes need to be stored in the NEON Intervention.
3. The Internet Protocol (IP) address of the computer
used to make a voucher claim will be monitored. For
each timepoint of the study, no more than 10
vouchers per IP address will be paid. This number
has been selected to allow for multiple eligible users
in the same residence, who might have different
logins to the NEON Intervention but share an
Internet connection—since domestic routers typically
assign the same IP address to all devices connected to
the router. It will also account for several individuals
accessing the NEON Intervention from the same
public computer (e.g. in a public library).
4. Unusual patterns such as more than 5 voucher
claims in a single day from an IP address will be
investigated by the study team. The study team will
contact relevant participants, using their registered
email address, to gather information about voucher
claims, and will reserve the right to suspend trial
participation and to withhold voucher payment if
suspicious behaviour is identified. Decisions will be
made by the Chief Investigator (CI), with reasons
reported to the study sponsor and logged in the
TMF. If trial participation is suspended, the
participant will not be included in study analyses.
Randomisation
Participants will then be randomised to either the
intervention group or the control group. The intended
allocation ratio (intervention group:control group) is 1:1
for all trials. No stratification of participants on any
baseline covariates will be conducted, as existing
research does not provide sufficient evidence to reliably
identify covariates [102]. Randomisation will be through
permuted block randomisation [103] with randomly
varying block length. This will use pre-computed lists
uploaded by an independent statistician.
Blinding of participants to allocation status is not
possible, given the design of the interventions. Control
group participants will be given a message reminding
them that they are still an important part of the trial,
and that they will receive access to the NEON
Intervention in 1 year. The current text is message 5 in
Additional file 8. Intervention group participants will be
told that they will receive immediate access to the
NEON Intervention, and asked not to share their login
details with others, to reduce contamination. The
current text is message 6 in Additional file 8. After
receiving this message, intervention group participants
are then taken to the “Welcome” page, as described in
the previous “Intervention group” section. At future
logins, intervention group participants go directly to the
intervention home page.
Control group participants are taken to a cut-down
version of the intervention home page, which only dis-
plays the “About NEON”, “About Me” and “I’m upset”
buttons. The About Me button links to a cut-down ver-
sion of the About Me page, which only allows for the
updating of contact information and for participants to
open a safety event reporting form.
Follow-up data collection
Participants will be asked to complete follow-up mea-
sures at the timepoints shown in Tables 1 and 2. A re-
quest will be sent using current contact information for
the participant, e.g. as collected through the online ICF
or updated through the “About Me” page. The request
will include a web address that allows the participant to
fill out outcome measures. Intervention group partici-
pants can also be prompted through the NEON Inter-
vention if they log into it at a timepoint when outcome
data can be collected.
When entering follow-up data, the same validation
procedures will be used as for baseline data collection,
and the same payment procedures will be used (i.e. a
£20 voucher will be offered on completion of measures
at each follow-up timepoint). Follow-up data will be
considered valid if provided within 2 weeks of the 1
week follow-up date, and if provided within 1 month of
all other follow-ups. Decisions on how to handle data
which falls outside of these windows will be detailed in
the statistical analysis plan (SAP). Incomplete forms will
remain available up until the start of the next follow-up
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period. For example, if a participant fails to fill out the
week 1 MANSA questionnaire, then the questionnaire
will remain available at next login up until the start of
the week 12 follow-up period, at which point the partici-
pant would receive the week 12 MANSA questionnaire.
At all follow-ups, all participants will be asked to
complete a recovery narrative usage questionnaire to track
contamination. To inform the process and economic
evaluation, at 52 weeks follow-up all intervention group
participants will be asked to complete a support received
questionnaire. Both are detailed in Additional file 2.
Reviewing consent and initiating withdrawal
Participants can view their consent form and initiate
withdrawal by logging into their account and viewing
the “About NEON” page, which is visible to both control
group and intervention group participants. This page
contains a button labelled Consent, which links to a page
providing options labelled (1) look at the consent form
and (2) I wish to withdraw from this study. If
participants select (2), they are shown a message
allowing them to either confirm their request, ask for a
discussion with a NEON researcher or cancel their
request. The current text is message 7 in Additional file
8. If they choose to withdraw, they receive message 8,
which tells them that all identifiable information has
been deleted, and tells them how to provide anonymous
feedback about the intervention. If they request a
discussion, they receive message 9, which tells them how
a researcher will get in contact with them. If they choose
to cancel their request, they are then taken to the
intervention home page.
End of study participation
Access to the NEON Intervention must close before the
end of the NEON study unless alternative funding
arrangements are identified. The end of a period of
engagement with a mental health technology needs to
be carefully managed, as it has the potential to be an
emotionally charged process, especially if the technology
has provided benefits to a user [67].
To support participants in the NEON trials through
the ending of their engagement with the NEON
Intervention, a message will be sent no later than a
month before a participant will lose access. This will
thank the person for his/her participation and inform
the participant of when he/she will lose access (message
10 in Additional file 8).
Once their participation has concluded, participants
will be sent message 11 (Additional file 8), which will
indicate other sources of recovery narratives that they
can consult, using a public list maintained by the NEON
study [104] and intended to remain publicly accessible
beyond the close of the NEON study.
Automated data logging
Logging data will be collected for a range of interactions
with NEON interfaces, to support accurate reporting of
the trial and for use in the clinical and process
evaluations. Only anonymous data will be logged until
consent procedures have been completed. Table 4
summarises the events logged about potential or enrolled
participants. Each event will be given a unique name to
distinguish it in the log files (e.g. ELIGIBILITY_START
for the first item in the table).
The following terms describe information logged
through this process:
 DATETIME: Date and time that an event took place.
Minimal recorded accuracy of one second (1 s)
 PPID: Potential participant ID. Temporary ID
allocated to potential participant so as to link data
they provide into trial records. Not linked to any
identifiable data until consent is given
 How Found: Primary care. Secondary care. Online
advert [name provider], Other
 Research site: Null, [any of the current secondary
care research sites]
 Allocated trial: NEON Trial, NEON-C Trial,
NEON-O Trial, Ineligible
 PIS item number: Number of the item being read on
the PIS (“1”, “2”, etc.)
 PIS action: Scroll up, Scroll down
 PIS item action: Expand, Collapse
 Participation decision: Participate, reject
 Process evaluation participation decision: Yes, no
 PID (Participant IDentifier): The unique ID allocated
to each participant after informed consent has been
given
 Form name: Demographics, MANSA, CORE-10,
Herth, MHCS, MIS, EQ-5D, CSRI
 Form items: All items on a demographics or
measures form
 NID (Narrative IDentifier): The unique ID allocated
to each recovery narrative by the NEON study team
before uploading to the NEON Intervention
 RID (Request IDentifier): The unique ID allocated to
each recovery narrative request
 SID (Session IDentifier): The unique ID allocated to
each session of usage of the NEON Intervention
 Allocated group: Intervention, control
 Route to Access: Content-based match, Collabora-
tive match, Random, Category, Hopeful, Book-
marked, First
 Access device: Mobile device, Computer
 Narrative feedback: As defined in the description of
the intervention
 Reminder Communication Mechanism: Email, SMS,
Facebook, etc.
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 About Me: A vector of (name,value) pairs
representing the set of values entered by the
participant using the About Me page
 Button name: About Me, I’m upset, Welcome, Get
me out of here
 Safety event type: Death, Life threatening event,
Hospital admission, Hospital stay extension,
Disability or incapacitation, Something else
 Caused by study: Yes, Unsure, No
 Date of event: Date that the safety event occurred
(but not time)
 Categories: Vector of categories used to narrow
down narrative, if category view used to find
narrative
 Q5 responses: All responses provided to Q5 in the
eligibility testing questionnaire.
Logs providing information about operation of the
online system as a whole and of the matching algorithm
will also be collected. These are summarised in Table 5.
The following terms describe information logged
through these processes:
 Parameter list: A vector of <name,value> pairs
describing the model produced by retraining
 Narratives: A list of NIDs added to the NEON
Intervention.
The “heartbeat” provides a mechanism for understanding
whether the online interface was available for participant
use at any given time. It will be recorded at a minimum
interval of 1 min (more regularly if possible within the
technical constraints of the web server hosting the
Table 4 Logs of participant system usage to collect
Event to log Information logged
Potential participants completes first question of eligibility
checking process
PPID, DATETIME
Potential participant completes eligibility checking process PPID, How Found, Research site, Allocated trial, Q5 responses, DATETIME
Potential participant expands or collapses item in the PIS PPID, PIS item number, PIS item action, Allocated trial, DATETIME
Potential participant navigates up or down through the PIS PPID, PIS action, Allocated trial, DATETIME
Potential participant makes decision about participation PPID, Participation decision, Allocated trial, DATETIME
Potential participant completes ICF PPID, Participation decision, Allocated Trial, Process evaluation participation decision,
DATETIME
Validation email sent PPID, DATETIME
Participant confirms participation by clicking link in validation
email
PPID, PID, DATETIME
Participant receives blank demographics/measures form PID, Form name, DATETIME
Participant submits complete demographics/measures form PID, Form name, Form items, DATETIME
Participant randomised PID, Allocated Trial, Allocated group, DATETIME
Participant logs into NEON Intervention PID, SID, Access device, DATETIME
Participant shown recovery narrative PID, SID, NID, RID, Route to Access, Categories, DATETIME
Participant provides narrative feedback RID, Narrative feedback, DATETIME
Participant logs out of NEON Intervention SID, DATETIME
Participant sent reminder about the NEON Intervention PID, Reminder Communication Mechanism, DATETIME
Participant changes information on About Me page PID, About Me, DATETIME
Participant requests payment of a voucher PID, DATETIME
Participant selects button in footer PID, Button name, RID (null if narrative not being viewed), DATETIME
Participant navigates to external URL PID, URL, DATETIME
Participant confirms withdrawal request PID, DATETIME
Participant blocks narrative PID, NID, DATETIME
Participant bookmarks narrative PID, NID, DATETIME
Participant unblocks narratives PID, DATETIME
Non-participant safety event reporting form submitted Safety event type, Caused by study, Date of event, Location of event, All other text on
form, DATETIME
Participant safety event reporting form submitted PID, Safety event type, Caused by study, Date of event, Location of event, All other
text on form DATETIME
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interface). This will be augmented by timestamps of the
moment when the system restarts for any reason, to 1-s ac-
curacy. Because crashes are caused by an unanticipated sys-
tem failure, it is not technically feasible to record the
precise moment when an unplanned system close-down
occurred. If a planned system close-down takes place (e.g.
for technical maintenance work), then this will be logged to
1-s accuracy.
Addition of new narratives to the NEON Intervention
New narratives may be added to the NEON Intervention
as the trials proceed. This will allow for the optimisation
of the NEON Intervention. The addition of new
narratives would be important if interim analyses of
demographic data show that participants have joined the
trials from groups who are under-represented in the
NEON Collection. It would also be important if some
participants used the NEON Intervention so regularly
that they were at risk of “running out” of new narratives
to access. The addition of a batch of new narratives may
incentivise re-engagement with the NEON Intervention,
and prompts might be sent to draw attention to the
presence of new narratives. If new narratives are added,
they will be added in a small number of batches, at in-
tervals of no less than 2 months. The date and contents
of each batch will be logged in the SAP.
Operation of the matching algorithm
The NEON Intervention is a hybrid recommender
system [54], which uses both collaborative filtering and
content-based filtering to match narratives to users.
When the user requests a new match, the list of narra-
tives presented to the user will include a small number
of items generated through each route. When narratives
in the match are accessed, logging will incorporate an
item indicating whether accessed narratives were recom-
mended through collaborative filtering or content-based
filtering, so that evaluation work can generate knowledge
on their relative importance.
Recommendations based on collaborative filtering will
identify narratives with characteristics which have
previously received positive narrative feedback scores
from users considered similar to the requesting user,
using a distance metric [105] calculated from user
characteristics listed in the personal profile and from
narrative feedback scores. Recommendations based on
content-based filtering will identify narratives whose
content is predicted to appeal to the requesting user.
This prediction will utilise a model developed through
supervised machine learning [57].
The supervised training process for this model
requires a training dataset, and a larger training set
typically leads to a more effective model. All three trials
will start with a single model trained from data collected
during the intervention development phase of the
NEON study (Slade, Rennick-Egglestone, Llewellyn-
Beardsley et al: Using recorded mental health recovery
narratives as a resource for others: Narrative Experiences
Online (NEON) intervention development, submitted).
This means that each trial will start with an identically
parameterised model. This model will then be retrained
using narrative feedback data provided by participants in
each of the three trials. The models used in each trial
will diverge, which is appropriate given the differing
study populations. Retraining will take place regularly
during the trial to maximise the benefits provided by
retraining. Retraining will be conducted at least once
during the internal pilot to assess the technical feasibility
of retraining the algorithm whilst the NEON Interven-
tion is still in use. At each retraining point, and in line
with objective 6, all parameters defining the model will
be logged, to allow for an understanding of how it has
developed. The retraining protocol used during the trial
will be logged in the SAP and included in the trial
report.
The NEON Intervention is intended to support
positive psychological change in the user. In order to
enable any change to influence the matching process, at
key points the user may be prompted to update user
characteristics stored in his/her personal profile. This is
most likely to lead to changes in the “Recovery status”
or “Diagnosis” item. Prompts might occur immediately
after filling out follow-up questionnaires at the 1 week
and 12 weeksfollow-ups. They would be sent by any
communication mechanism in the personal profile after
receiving each batch of 25 narratives. Older narrative
feedback scores will be reduced in weight and eventually
discarded for the purpose of calculating preference simi-
larity with other users in collaborative filtering. This re-
flects the assumption that psychological change might
be manifested in changes in narrative feedback
behaviour.
We anticipate that the effectiveness of the matching
algorithm will improve over time. Recommendations
made by collaborative filtering are likely to improve as
new participants join the trials, since a larger number of
participants may mean a more precise identification of
others who are similar to the participant requesting a
Table 5 Logs of system operation
Item Information logged
Heartbeat DATETIME
Planned system close-down DATETIME
Planned system restart DATETIME
Unplanned system restart DATETIME
Model retrained DATETIME, Parameters
Narrative batch added DATETIME, Narratives
Rennick-Egglestone et al. Trials          (2020) 21:661 Page 20 of 34
match. Recommendations made by content-based filter-
ing are likely to improve as new content is added, as this
provides for a greater pool of content, and as the model
used to match participants to content is refined.
Qualitative process evaluation data collection
Qualitative process evaluation data will be collected
from the following groups:
1. The first 30 intervention group participants in the
NEON Trial will form an internal pilot group. Each
will be offered the opportunity to take part in the
process evaluation of the internal pilot, at least 2
weeks after randomisation.
2. Any NEON Trial participants who withdraw their
consent for participation (the withdrawal of consent
group) will be given the opportunity to tell the
research team by email about how NEON can be
improved. As they are no longer participating in the
trial, they will not be interviewed but simply given
the opportunity to provide feedback, which will be
retained anonymously. Beyond clarifying any
ambiguities, dialogue will not be entered into
following the receipt of any feedback, other than to
thank the persons for their feedback.
3. Intervention group participants for the NEON Trial
will be offered the opportunity to take part in the
process evaluation of the trial at the end of their 1-
year participation. Interviewing will continue with
this group until either theoretical saturation occurs
or 50 interviews have been completed, whichever is
sooner. Up to 20 participants in the NEON-C and
NEON-O trials will be invited to a process evalu-
ation interview.
4. If attrition is significant from the NEON Trial,
interviews with up to 20 intervention group
participants who only minimally used the
intervention (low engagement group) will also be
conducted, to understand the perspective of people
who may not have found the intervention useful.
Participants in the internal pilot, intervention and low
engagement groups will be contacted using their current
contact information and asked to participate in an
interview with a researcher by phone or secure video
conference. At the start of the interview, the researcher
will remind the participant that his/her participation is
voluntary, that participation in the interview will be
confidential and that only anonymised transcripts will be
used in analysis. The participant will be asked to
confirm that he/she consents to take part. These
conversations will be captured in the audio recording of
the interview. They will also be recorded onto a paper
consent form by the researcher (Additional file 11). In
all cases, participants can ask for an interview with a
peer researcher if preferred. £20 will be offered to all
participants as compensation for time and effort
incurred, payable by electronic voucher or submission of
a claim forms.
Interviews with the internal pilot group will focus on
assessing the fidelity and safety of the intervention. This
will allow the Programme Steering Committee (PSC) to
make any necessary decisions about changes to study
procedures following on from the internal pilot. The
topic guide for internal pilot interviews will include
questions intended to identify safety issues, to ascertain
whether the NEON Intervention has been experienced
as intended and to identify factors limiting fidelity, such
as technical problems experienced by participants, or
features of the interface limiting accessibility. Internal
pilot interviews will take a maximum of 1 h.
Interviews with the intervention and low engagement
groups will be broader for NEON Trial participants. A
draft topic guide is shown in Additional file 12. In line
with qualitative methodologies, the interview schedule
will be refined over time. During the interview, some
intervention group participants will be shown
visualisations of logging data collected by the NEON
Intervention and asked to explain interesting or unusual
patterns, such as periods of very heavy or very light
usage. This is a standard approach to enabling reflection
on computer system usage [106], and it provides a
mechanism for augmenting system logs with the cause
of such phenomena. Interviews with the intervention
group for the NEON-O Trial and NEON-C Trial will be
shorter, and will focus on the acceptability of the inter-
vention to these participants.
Resilience to unplanned system downtime
Occasional unplanned system downtime is to be
expected with online interventions. A 2018 study of 32
web-hosting providers estimated 35 h downtime per year
[107]. This makes it likely that some participants or po-
tential participants will experience unexpected downtime
whilst using the NEON Intervention.
Unexpected downtime might occur before consent has
been provided by a potential participant. In this
scenario, potential participants will need to complete
eligibility checking processes again. Since no identifying
information about potential participants can be collected
until consent has been provided, it will not be possible
to inform potential participants of the need to
recomplete eligibility checking processes.
Unexpected downtime might occur after consent has
been provided but before randomisation has been
completed, e.g. partway through completing demographics
and measures forms. In this scenario, a participant can
continue completing demographics and measures forms
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the next time he/she logs in. Data will be retained from any
completed forms and will not need to be re-entered. In the
event of this scenario, the participant will be sent a re-
minder of the need to complete demographics and mea-
sures, by any contact mechanism they have specified on the
consent form. This reminder will be sent at least 1 day after
the first form was completed.
Unexpected downtime might occur after a participant
has been randomised. This is inconsequential for trial
processes, and hence no specific response is needed.
Safety event monitoring, response and reporting
Study principles For all three trials, only serious adverse
events (SAEs) will be monitored. This study policy has
been agreed on with the PSC and study sponsor. It is
consistent with HRA guidance, which indicates that only
SAEs which are unexpected and related to the study
should be reported to the Research Ethics Committee
(REC) [108]. It has been informed by the online nature
of the trials described in this protocol. Since the trials
have no planned routine face-to-face contact with clin-
ical or research staff, this would make routine monitor-
ing for non-serious adverse events (AEs) intrusive. No
event monitoring or reporting will take place after the
trial has closed, even if a reported event pre-dated the
end of the trial.
The HRA defines an SAE [108] as an untoward
occurrence that:
1. Results in death
2. Is life threatening
3. Requires hospitalisation or prolongation of existing
hospitalisation
4. Results in persistent or significant disability or
incapacity
5. Consists of a congenital anomaly or birth defect; or
6. Is otherwise considered medically significant by the
investigator.
The following AEs may result in an SAE and can be
reasonably expected from this study, having been
identified from the trial change model presented in
Fig. 1. As they are expected, they will not be reported to
the REC, in keeping with protocols established for other
online studies [109]. All items in this list are specifically
identified in the PIS as a possible harm of taking part in
the trial so that potential participants can make an
informed choice about participation:
 Feeling disconnected from others
 Feeling more pessimistic
 Feeling emotionally burdened
 Feeling inadequate
 Experiencing the release of uncomfortable emotions
 Engaging in harmful behaviours encountered in
narratives.
In the event of uncertainty about whether an SAE
should be categorised as unexpected, the CI can ask for
a categorisation recommendation from the PSC chair.
All SAEs, regardless of categorisation, will also be
reported in an anonymous form to the PSC in case a
specific response is indicated, such as a change to trial
procedures. If a Data Monitoring Committee (DMC) is
formed, then the event will be communicated to the
DMC with all participant details intact.
Safety event monitoring procedures Since these are
online trials with no face-to-face contact, it is likely that
the CI will not become aware of all SAEs. The following
procedures have been selected to create the maximum
opportunity for SAE reporting:
 The version of the CSRI used in all three trials
includes questions on nights spent in hospital and
admissions to other hospital-based services. When
used in the 12 months follow-up assessment, the
retrospective period for the abridged CSRI is 12
months, which covers the entire duration of partici-
pation in the trial. As such, if a number other than 0
is entered for any of these questions, this could indi-
cate that an SAE of type 3 as listed above has oc-
curred, although it is still possible that the
hospitalisation was planned, such as an operation for
a physical health problem. Follow-up questions will
be asked through the online form to collect suffi-
cient details to allow for an event to be identified
and categorised. Specific questions are included in
Additional file 2.
 The splash page for the NEON Intervention will
include a link to an online safety reporting form for
use by participants or non-participants, which will
allow SAEs of all types to be reported. Questions in-
cluded in the safety reporting form are included in
Additional file 13. After completing the form, the re-
spondent will be given a message informing them
that the report has been received. The respondent
cannot be informed of how it will be processed, as
this would breach the confidentiality of any partici-
pant that they reported on.
 The “About Me” page will include a link to an
online safety reporting form, which allows
participants to report SAEs (see Additional file 13).
After completing the form, the respondent will be
given a message thanking them for the report. Since
this form is only accessible to the participant, it will
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exclude type 1 SAEs, as the participant cannot
complete this form if he/she has died.
When an SAE is identified through an online form, an
email notification of the SAE and all accompanying
information will be sent to the CI and study coordinator.
Members of the study team or research site teams may
also become aware of AEs through a direct communication
from a participant or third party such as a family member
or clinician. Some of these events may be classifiable as
SAEs. Team members may become aware of these events:
 By email or phone, using contact details provided on
the PIS or which are otherwise available publicly
 Through discussions in process evaluation
interviews.
Any generic email address or phone number used by
the study team will include a message indicating how
regularly it will be monitored, and indicating that a
response will be generated by the study team within a
maximum of 3 days.
Since the study policy is only to monitor SAEs, the
person receiving a communication will first assess the
event. All individuals who might receive AEs will
undertake Good Clinical Practice (GCP) training in
advance of trial start to support them in understanding
how to respond and categorise them, and appropriate
supervision arrangements will be in place to support
their practice and safety.
If the received communication relates to participant
difficulties that do not reach the threshold for an SAE,
the person sending the communication will be sign-
posted to the support options identified through the
“I’m upset” button, which is available to both the inter-
vention group and the control group. If participant diffi-
culties do reach the threshold for an SAE, the
communicator will be asked about whether the study
contributed to the event and also for further details of
the event and its cause. The CI and study coordinator
will be immediately informed of the event and the details
that have been collected. If the person receiving the
communication has any doubt about how to categorise
the event, he/she will proceed on the assumption that it
is an SAE, and the event will be referred to the CI.
In all reporting routes, if further information is needed
about the event, the CI or a delegate will attempt to
contact the respondent for further details. If contact
cannot be established with the respondent within 3 days,
the CI will log this and will make decisions based on
available information.
Safety event categorisation and reporting The CI will
assess all events reported to him, using all available
information. If the event is categorised as being an SAE
that is both unexpected and related to the study, it will be
reported to the REC, study sponsor, PSC and DMC if
formed, within 15 days of the CI becoming aware of it. All
SAEs will also be reported to the PSC chair, who will
decide how to respond in collaboration with the CI.
Options include no response; a direct recommendation to
the CI from the PSC chair; or referral of the SAE to the
full PSC or DMC for discussion and recommendation.
Emergency unblinding The online interface used by the
NEON trials will provide a function to reveal the
allocation status of a single participant based on their
ID, so as to enable emergency unblinding. This will only
be accessible to the CI and study coordinator. Use of
this function will be logged for the purposes of audit.
Data handling and record keeping
Data management Electronic trial data will initially be
collected through an application running on a secure
web server and placing data into a secure database. The
application, web server and database will be controlled
by DRT Software, an IT supplier with a contractual
arrangement to the study sponsor to control the data
processing operations that can be performed, which will
be specified in the delegation of duties log. The web
server and database will be hosted by a web-hosting pro-
vider contracted to DRT Software. The web-hosting pro-
vider will be accredited an information security standard
agreed on with the study sponsor in advance of trial start
(such as Cyber Essentials or ISO 27001). The application
will not be opened to trial participation until the study
sponsor has agreed in writing that hosting arrangements
meet appropriate levels of security for hosting sensitive
personal information.
In the application, information that might identify an
individual (e.g. email or phone numbers provided
through the consent form) will be stored in a separate
database from anonymous research data, linked only by
ID. All information will be encrypted at rest using 256-
bit Advanced Encryption Standard (AES) encryption or
equivalent, or stronger. A backup process will be speci-
fied in a data management plan agreed on with the Prag-
matic Clinical Trials Unit (PCTU), IT supplier and study
sponsor, and all backups will be encrypted at rest. All in-
formation will be encrypted in transmission to and from
the server using Hypertext Transfer Protocol Secure
(HTTPS). At close of trial, all data stored on the web
server, database and associated backups will be deleted
using a thorough deletion protocol. When logging data
from the trials is copied off the server, this will be logged
so as to reveal who has accessed unblinded research
data. For analysis and storage until end of the NEON
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study, anonymous research data will be transferred over
HTTPS to a research server managed by the University
of Nottingham.
The exception to these arrangements will be qualitative
process evaluation interview data. Interviews will be carried
out by either telephone or secure video conference.
Recordings of interviews will be made on computers with
encrypted hard drives and/or to encrypted audio recorders.
As soon as possible, data will be copied onto research
servers managed by the University of Nottingham and then
deleted from the source device.
All data placed onto University of Nottingham
research servers is backed up to two geographically
redundant backup systems. Initially, the CI will only
delegate access to the research team and study sponsor
(the latter for the purposes of audit only). The research
team incorporates staff at the University of Nottingham,
PCTU, King’s College London, University of Manchester
and Queen Mary University of London. If researchers
work at sites other than the University of Nottingham,
they will be able to download anonymous research for
analysis using an individual associate account and a
secure file transfer protocol. Alternatively, external
researchers will be able to access data and analysis
software using a remote desktop application, working
over a secure connection. Consent logs will also be
transferred to the same research servers, but to a
different location and with access initially limited to the
CI, and then delegated if necessary using the delegation
of duties log.
All of these procedures will be approved in writing by
the study sponsor before the trial opens to participants,
and approvals will be deposited in the TMF. The study
sponsor will be the Data Controller for personal
information, and the IT contractor, web-hosting pro-
vider and University of Nottingham will be data proces-
sors. Data processing operations will only be entered
into when satisfactory contracts are in place to control
data processing operations, such as collaboration agree-
ments. All processing of personally identifiable data will
be logged, in keeping with General Data Protection
Regulation (GDPR) requirements.
Where research data is provided directly by participants,
e.g. by completing electronic forms presenting items from
demographics or outcome measures, the design of these
forms will be reviewed by a PCTU-approved statistician
before use, and they will not be used to collect data until
signed off by the statistician.
Confidentiality Procedures for separation of identifying
and anonymous data are recorded as above. All
participation will be confidential. Confidentially will only
be breached if, following a contact with a research team
member, the CI decides that a participant is at risk to
self or other, or has committed a notifiable offense. In
this circumstance, consent logs will be searched for
information that can be used to contact the person, and
if possible the confidentiality breach will be agreed on
with the participant in advance. If agreement cannot be
reached, the CI may choose to pass on contact
information to a relevant statutory authority.
Record retention and archiving The body with
responsibility for archiving of records beyond the end of
the NEON study is Nottinghamshire Healthcare NHS
Foundation Trust. For non-CTIMP studies, the funder
indicates that the sponsor stipulates retention and ar-
chiving policies [110] (see subpage on archiving). The
sponsor indicates a minimum retention period of 5 years
for all records generated by this study.
Annual reporting
The CI will also send Annual Progress Reports to the
trial REC and the sponsor using the HRA template. This
will occur within 30 days of the anniversary of receiving
the REC “favourable opinion”.
Monitoring and auditing
The sponsor or delegate retains the right to audit any
study, study site or central facility. In addition, any part
of the study may be audited by the funders where
applicable. Audits will include the contents of the TMF
and Investigator Site File (ISF) (to ensure compliance
with Standard Operating Procedures [SOPs]).
Study committees
All three trials will be overseen by an independent
Programme Steering Committee (PSC), which will
function as a Trial Steering Committee (TSC). This
committee has previously been convened by the CI. The
chair of the PSC is Professor Sonia Johnson (Professor
of Social and Community Psychiatry, University College
London). Other members are Dr Tom Barker (Oxford
NHS Foundation Trust), Dr Stephen Bremner (Senior
Lecturer in Medical Statistics, Brighton & Sussex
Medical School), Terry Harper (independent Patient and
Public Involvement [PPI] representative, current mental
health service user) and Paul Stevens (Peer Support
Worker, Worcestershire Health and Care NHS Trust).
Any changes in PSC membership will be reported to the
funder, study sponsor, PCTU and REC. Minutes of PSC
meetings will be placed in the TMF and reported to the
funder, study sponsor and PCTU.
The CI and the PSC will decide whether to form a
DMC, whose charter will be to identify ethical or safety
issues emerging during the NEON Trial. The CI will
inform the funder, study sponsor, PCTU and REC of a
decision to form a DMC and its membership, or will
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provide a justification if a DMC is not formed. The
DMC is the only body to have access to unblinded
outcome data.
At 2 months, the study team will review recruitment
and retention for all three trials. If needed, and with
advice from the PSC, the study team will implement
low-burden contingency plans such as extending the re-
cruitment strategy. Examples would include obtaining
support from charities in advertising the opportunity to
participate.
Once the analysis of the internal pilot is complete (at 4
months or slightly later), the PSC will be presented with
information about the fidelity, safety and recruitment/
engagement performance of the internal pilot. Safety
information will include:
 Anonymous summaries of all SAEs received,
including details of which (if any) were classified as
being both related to the study and unexpected
 Anonymous analyses of elements of interview
transcripts relating to safety.
The PSC will consider this information and decide
whether to recommend changes to study procedures;
whether to invoke remedial measures on recruitment
and engagement; and whether to take forward data
collected through the internal pilot into the full trial. For
pragmatic trials, the latter is known to be a subjective
judgement [111].
The PSC will also decide whether to invoke specific
remedial measures to recruitment and engagement. The
criteria for invoking these measures are as follows:
recruitment, at or near 147 participants recruited within
the first 4 months (i.e. 75% of target); engagement, 90%
of intervention group participants view one narrative
within 48 h of randomisation.
Remedial action to take would be decided by the PSC
and identified in collaboration with the NEON Trial
Management Group (TMG), which is composed of
representatives of the NEON study research team, LEAP
and PCTU. Examples of possible remedial strategies for
recruitment include reducing the follow-up length to
allow longer for recruitment or widening recruitment
beyond England. Examples of remedial strategies for en-
gagement include the addition of face-to-face facilitation
by either researchers or local clinical staff. The analysis
plan for the NEON Trial will be updated accordingly,
and any changes would be summarised in the NEON
Trial report.
At 6 months the PSC may again formally review
recruitment and engagement in order to decide whether
the NEON Trial should continue. The stop/go rule for
recruitment will be attainment of, or clear trend
towards, 206 (70%) of target 294 participants in this
period. The stop/go rule for engagement will be
attainment of, or clear trend towards, 80% of
participants view one narrative within 48 h of
randomisation. There are no stop/go rules for the
NEON-C or NEON-O trials, but if the NEON Trial is
stopped, these two trials will be stopped as well.
A representative of the study funder will be invited to
all PSC meetings. Changes to the study considered
minor (in the judgement of the PSC chair) will be
considered implementable immediately. Major changes
will be referred to the funder for review before
implementation.
Operating procedures for the trials
Unless otherwise stated, the SOPs of Queen Mary
University of London PCTU will be used for these trials.
These include procedures for notifying relevant parties
of protocol updates.
Analysis
The trial statisticians conducting statistical analysis work
and the NEON CI will be blinded in relation to
allocation status until the statistical analysis plan (SAP)
is signed off, all follow-up data is collected and data
cleaning has occurred. Blinding will be through the use
of access control lists in the file store used to aggregate
data from the NEON Trials.
To maintain blinding for any interim reports, an
independent statistician will prepare any information
which requires knowledge of treatment allocations or
involves data which would allow treatment allocations to
be determined.
Statistical significance will be assessed at the 5% level,
unless otherwise stated. Participant flow through the
trial will be summarised in a Consolidated Standards of
Reporting Trials (CONSORT) flow diagram [112].
Internal pilot evaluation for the NEON Trial
Analysis of the internal pilot of the NEON Trial will
evaluate factors negatively affecting the fidelity of the
NEON Intervention, identify any issues affecting the
safety of participants and evaluate the recruitment
process for the NEON Trial. These categories have been
selected from the broader set of categories in the
acceptance checklist for clinical effectiveness pilot trials
(ACCEPT) [111].
There are three sources of data for the internal pilot
evaluation: (1) anonymous transcripts of interviews with
up to 30 intervention group participants, (2) system
operation logs for the first 3 months of operation of the
NEON Intervention, (3) logs of the first 3 months of
participant flow through the NEON Intervention.
Factors affecting safety will be identified through an
inductive thematic analysis of interview data. If analysis work
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identifies specific events which have occurred for individuals,
then the procedure for handling these is described in the
section on “Safety event monitoring procedures.”
Fidelity will be evaluated through (1) an inductive
thematic analysis of interview data to identify factors
negatively affecting fidelity and (2) a descriptive analysis
of system operation logs to quantify system downtime
and the impact on participants of downtime (e.g. by
estimating numbers of participants using the system at
each period where it became unavailable).
The recruitment process will be evaluated through the
production of an interim CONSORT diagram [112] for
the internal pilot and a table summarising recruitment
routes used, and for each route identifying number of
eligible participants, number of participants randomised,
cost of recruitment.
Descriptive analysis for the NEON Trial
Only participants who have completed baseline
measures and been randomised will be included in
descriptive analyses.
Demographic and clinical outcomes at baseline will be
summarised by treatment group. Demographic information
will include all items collected on the baseline demographics
form with age presented as mean (SD) and the remaining
categorical variables presented as n (%). Clinical outcomes
will include quality of life, as measured by the mean item
score of the MANSA questionnaire; symptomatology, as
measured by the total score of the CORE-10 questionnaire;
hope, as measured by the total score of the Herth Hope
Index; empowerment, as measured by the Mental Health
Confidence Scale; and meaning in life, as measured by the
mean item score on the presence and search subscales of the
Meaning in Life Questionnaire. Higher scores indicate better
outcomes in all but the CORE-10 measurement scales. Nor-
mally distributed data will be summarised by mean (SD);
non-normally distributed data will be presented as median
(interquartile range [IQR]).
For those in the intervention group, engagement will
be summarised as the mean (and range) number of
times a participant logs into NEON, receives a recovery
narrative and provides a narrative feedback.
SAEs, withdrawals and timing of withdrawals from the
trial will be summarised as n (%) by treatment group.
The number (percentage) of missing data on the
demographics questionnaire and all clinical outcomes at
baseline and follow-up timepoints will be summarised,
and possible reasons for the missing data described and
discussed.
Clinical outcomes evaluation
Only participants who have completed baseline
measures and been randomised will be included in
clinical outcomes analyses.
Primary outcome analysis for the NEON Trial The
primary outcome is the mean item score of MANSA at
52 weeks. Descriptive statistics of mean and median
scores with SD and IQR will be presented by treatment
group. Analysis will follow intention-to-treat (ITT) prin-
ciples. The primary analysis will be a linear regression
model of outcome at 52 weeks adjusting for baseline
score and selected demographics. The results will be
presented as adjusted difference in score at 1 year
follow-up with associated 95% confidence intervals.
The missing data mechanism will be assumed to be
missing at random (MAR) [113] unless evidence of
violation is found. Under this assumption, missing data
for the primary and key secondary analyses will be
imputed using multiple imputation. The number of
datasets generated will reflect the percentage of missing
data present. Individual analyses on each imputed
dataset will be combined using Rubin’s rules [113]. The
imputation model will account for the longitudinal
nature of the outcomes, and will include all variables
contained in the substantive model and auxiliary
variables which help to support the MAR assumption.
Robustness of inferences to the MAR assumption will be
explored through sensitivity analysis.
Secondary outcomes analysis for the NEON Trial The
secondary outcomes are total scores at 52 weeks of the
CORE-10, Herth Hope Index and Mental Health Confi-
dence Scale, and the mean item score on the presence
and search subscales of the Meaning in Life Question-
naire. Descriptive statistics of mean and median score
with SD and IQR will be presented by treatment group.
Analysis will follow ITT principles and be conducted on
the imputed dataset. The analysis of each outcome will
be a linear regression model of outcome at 52 weeks
adjusting for baseline score. The results will be pre-
sented as adjusted difference in score at 1 year follow-up
with associated 95% confidence intervals.
The primary analysis will be repeated to include an
interaction term between treatment and service user
type at baseline (primary care service user, secondary
care mental health service user, no prior mental health
service use) to explore any differential treatment effect
amongst service user types.
As a secondary analysis, to investigate differences in
intervention effect over time, the primary outcome will
be analysed by a linear mixed model with a random
effect for participant.
Where outcomes are identified to be non-normally distrib-
uted, appropriate transformation or non-parametric analyses
will be performed and detailed in the SAP.
Exploratory analysis of the NEON Trial Exploratory
analysis using the intervention group only will examine
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the patterns of intervention use, predictors of
intervention use and association of usage with clinical
outcome. Measures of usage include the number of
stories accessed and the number of complete sets of
narrative feedback stories provided.
Univariate associations between each usage measure
and demographic and baseline clinical characteristics
will be assessed by a Poisson regression model with the
usage period (defined as the number of days between
first and last log in) included as an offset term.
Linear or non-linear regression, as appropriate, will be
used to assess the association of each usage measure
with the MANSA score at 52 weeks.
To determine which variables and relationships may
be important for consideration in the design and
analysis of future trials, a model selection procedure will
be conducted for the MANSA score at 52 weeks.
Since new narratives will be added to the NEON
Intervention during the trial, and since retraining will be
conducted on the machine learning algorithm used in
the matching process, we will explore the possible
impact on effect size of adding narratives and re-training
the algorithm.
Exploratory analysis of the NEON-C and NEON-O
trials An exploratory analysis of outcome measures will
be conducted using the same principles as for the
NEON Trial. A preliminary effect size estimate will be
made if recruitment and retention rates indicate this is
statistically justified. This will support choice of
outcome measures for a future definitive trial. All
reporting will indicate that this was an exploratory trial.
Economic evaluation of the NEON Trial
Only participants who have completed baseline
measures and been randomised will be included in
economic analyses.
The economic evaluation will evaluate the costs of
offering the NEON Intervention. It will present results
with set-up costs both included (sensitivity analysis) and
excluded (base case). Expected costs of offering the
intervention include costs of (1) developing the software,
(2) operating the online intervention, (3) periodically up-
grading the software and updating narratives and (4)
hosting the software on a server (including maintenance
costs, server space, technical support and licensing ar-
rangements). The impact of receiving the intervention
on service costs will also be calculated, using service use
data collected through the abridged Client Service Re-
ceipt Inventory (CSRI).
Outcomes Quality-adjusted life years (QALYs) will be
calculated by attaching available utility weights to the
health states generated from the EQ-5D-5 L, using area
under the curve methods with an assumption of a linear
change between timepoints.
Incremental economic analysis The economic
evaluation has been designed using standard reporting
criteria [114].The estimation of cost-effectiveness ratios
will be carried out using the payer’s perspective (NHS
England). Incremental cost-effectiveness ratios will be
calculated in the event of the intervention having higher
costs and better outcomes (based on EQ-5D-5 L and
MANSA). Disaggregated costs and outcomes, and both
deterministic and probabilistic incremental cost-
effectiveness ratios, will be presented. The base case ana-
lysis will incorporate only NHS and Personal Social Ser-
vices (PSS) costs and will express costs incurred in
terms of QALY gain. Uncertainty will be addressed by
generating cost-effectiveness planes from bootstrapped
resamples. Cost-effectiveness acceptability curves will be
constructed to show the probability that the intervention
is cost-effective for different cost-per-QALY thresholds.
Further sensitivity analyses will examine (separately
and together) the effects of expressing incremental
changes in cost in terms of changes in MANSA;
incorporating lost work; including intervention set-up
costs; and variability in service delivery and uptake as
determined during the RCT and process evaluation.
Given the expected attrition of service user response,
standard multiple imputation approaches to missingness
will be employed and the effects on cost-effectiveness es-
timates will be examined.
Process evaluation analysis
Process evaluation analysis for the NEON Trial will
follow best practice guidance [115, 116]. It will consider
fidelity, reach, dose and adherence and also acceptability
for the NEON Intervention. It will also evaluate the
NEON change model for the study population and
identify any safety issues relevant to future use of the
NEON Intervention. The analysis will integrate
quantitative data collected electronically through the
NEON Intervention and qualitative data collected
through interviews with three groups (withdrawal of
consent, intervention, low engagers). Across all process
evaluation analysis work, a particular focus will be on
understanding the experience of participants who have
never used mental health services, to generate
knowledge about usage of the intervention by a large
and under-researched group. This will amount to a
planned subgroup analysis of all participants who self-
identify as a member of this group through the trial
demographics form. Process evaluation analyses for the
NEON-O Trial and NEON-C Trial will be much more
limited and will primarily focus on acceptability, through
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the analysis of qualitative interview data and logged
intervention usage data.
Fidelity We will evaluate factors that enabled or blocked
usage of the NEON Intervention as a technology for
delivering recorded recovery narratives. This will include
quantitative analyses of logging data to identify periods
of uptime and downtime for the NEON Intervention
and the implications of participation for downtime, and
the identification of factors enabling or blocking usage
through interview analysis, such as difficulties obtaining
access to computers or networks as a form of digital
exclusion [117].
Reach The reach of the NEON Trial will be investigated by
analysing sociodemographic, clinical and geographic
characteristics of participants to consider representativeness.
For example, the sociodemographic profile of participants
will be investigated to identify if there are groups who would
be expected to but are not accessing the intervention,
supplemented by qualitative data revealing any specific
problems with accessibility.
Dose and adherence There is no desired “dose” of
recovery narratives received and no desired pattern of
adherence to treatment, as even receiving just one
recovery narrative might produce life-changing results.
Rather, since no definitive trial of the use of recorded re-
covery narratives in the treatment of psychosis has been
conducted, the aim of this part of the process evaluation
will be to provide an understanding of patterns of receiv-
ing recovery narratives, and to explore their relationship
to outcomes. This will support future clinical and non-
clinical use of the NEON Intervention.
To provide an understanding of how the intervention was
used, summary statistics will be presented for intervention
use using data collected in the NEON Intervention logs.
Duration of engagement will be calculated as number of
days from baseline to final narrative received for each
participant. Number of recovery narratives accessed per
week of the intervention will be calculated using completion
of all three narrative feedback questions as an indicator that
the narrative has been processed in full. Summary statistics
showing number of recovery narratives accessed in total
versus number of recovery narratives accessed and feedback
provided for will be presented.
Acceptability
The acceptability of the intervention will be evaluated
through a deductive analysis of interview data. This will
utilise existing frameworks [118] to structure transcript
fragments.
Evaluation of the NEON change model The NEON
change model will be evaluated through qualitative
analysis of interview data. Thematic analysis will be
applied, using a hybrid deductive-inductive approach.
An initial coding framework will be produced using con-
cepts named in the trial change model, and this will be
extended inductively by application to interview data, to
allow accounting for unanticipated forms of change.
Analysis will be supplemented by consideration of quan-
titative data, e.g. the extent to which high connection
was associated with high hope-promotion, as assessed
using narrative feedback scores.
Safety of the NEON Intervention Factors relating to
the safety of the NEON Intervention will be evaluated
through qualitative analysis of interview data. Thematic
analysis will be applied, using a hybrid deductive-
inductive approach. This will begin with codes relating
to safety developed through the qualitative analysis of
the internal pilot (if any), which will be extended induct-
ively through application to interview data.
Evaluation of the supervised machine learning algorithm
The performance of the selected supervised machine
learning algorithm in training a model to do content-
based recommendation will be evaluated, led by Jeroen
Keppens, a machine learning expert who is an investiga-
tor on the NEON study. Firstly, models used by the al-
gorithm during the NEON Trial will be inspected and
described, providing information about types of match-
ing data that were influential/not influential in the
NEON Trial matching process. The generalisations gen-
erated by the model will be compared against first prin-
ciples by examining whether they fit the domain
literature and patterns observed by mental health re-
searchers in this study.
The performance of the supervised machine learning
algorithm will be evaluated by comparing its performance to
that of a range of standard supervised machine learning
algorithms suitable for recommendation systems. To enable
this comparison and to ensure that the evaluation assesses
how well each algorithm generalises to unseen data, all
available recovery narrative feedback data generated during
the NEON Trial will be partitioned into a training dataset
and a validation dataset. This process is repeated over
different partitions of the dataset into training and validation
datasets [119].
The performance evaluation of each algorithm will
utilise a vector metric calculated from logged narrative
feedback data. Better algorithms will be defined as those
that recommend narratives that score highly on one or
more of these criteria. To assess the quality of a model
produced by a machine learning algorithm, standard
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assessments of precision and recall in reproducing a top-
N of narratives will be employed [120].
Discussion
Approaches to reducing bias
The following approaches to reducing bias in clinical
trials [121] have been adopted for all three trials.
Selection bias
To minimise baseline differences between groups, all
participants will be randomly allocated using an allocation
algorithm validated by the overseeing Pragmatic Clinical
Trials Unit (PCTU).
Detection bias
To eliminate any differences in how outcomes are
measured, all participants will only provide outcome
data through an online interface, which will be identical
for each group.
Attrition bias
To reduce differences in attrition between the control
and intervention groups, control group participants will
be told that they will receive access to the NEON
Intervention after the primary endpoint, and all
participants will be compensated for the time and effort
of providing outcome data.
Reporting bias
International Standard Randomised Controlled Trials
Numbers (ISRCTNs) have been registered for all three
trials; the trial report will be published open access; and
a summary of trial results will be provided on the
NEON study website.
Contamination bias
To avoid contamination through being allocated to the
intervention group in one trial and the control group in
another, individuals will only be allowed to take part in
one trial.
Contamination is otherwise possible in three ways:
1. A participant allocated to the control group could
repeatedly register until allocated to the
intervention group. This will be minimised by not
allowing the creation of a new login using the same
email address as an existing login.
2. A participant allocated to the control group could
request and use the login details from an
intervention group participant. This risk is low
because recruitment is online, so participants will
not generally know who else is participating. This
will be further minimised by asking all participants
not to share their login details.
3. Deciding to participate in the trial might prompt
participants to access publicly available narrative
repositories (e.g. YouTube), or a participant may
receive narratives through clinical care (e.g. from a
peer support worker). To monitor this form of
contamination, all participants will be asked at
follow-up about access to recovery narratives out-
side of the NEON Intervention.
Support for safe interaction with the NEON Intervention
A broad range of measures have been incorporated into
the design of the NEON Intervention and the study
procedures for the three trials to enable safe usage.
These approaches have been developed in consultation
with the NEON LEAP and NEON International
Advisory Board (IAB).
1. Potential participants will be informed through the
Participant Information Sheet (PIS) about forms of
harm that can be caused by receiving recovery
narratives, to enable an informed choice about
participation. This information draws on the results
of research conducted by the NEON study [4, 5]. It
will provide participants with knowledge to support
self-management.
2. All narratives used in the NEON Intervention will
first be characterised by researchers, using the
Inventory of the Characteristics of Recovery Stories
(INCRESE) , which has been developed by the
NEON team. This includes items to identify
narratives which should have content warning(s)
about potentially distressing content. For the
NEON trials, the characteristics of each narrative
included in the NEON Intervention will be rated by
a single researcher using INCRESE. Additionally,
since our testing indicates that it is not possible to
identify narratives requiring content warning with
100% accuracy because of differences in rater
interpretation about content, items relating to
content warnings will be second-rated by a separate
rater. If either rater identifies a content warning as
relevant, it will be applied. Narratives including dis-
tressing content should not be excluded, as content
which is distressing for some will provide benefits
to others [5].
3. The Initial information page, which is the first page
encountered in the NEON Intervention, will enable
intervention group participants to specify categories
of potentially distressing content that they wish to
avoid, and this preference can be updated through
the About Me page. Narratives identified by raters
as including that content will never be visible to
participants. Being able to exclude all narratives
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including a particular type of content is a form of
self-management.
4. If a narrative is identified as including a type of
potentially distressing content which has not been
excluded by a participant, then before the
participant accesses this narrative, he/she will be
shown a content warning and given the choice of
whether to continue or not.
5. Users can block a narrative that they find
distressing, and this narrative will not be listed in
the NEON Intervention until unblocked.
6. Self-management strategies identified by
participants at first login are shown to them when
they click the “I’m upset” button.
7. At first login, the Useful Information page will
provide brief advice on how to handle difficult
emotional responses to narratives, and further
advice will be provided on the “I’m upset” page.
This information will always be available through
the footer of the NEON Intervention.
8. A button labelled “Get me out of here” is provided
in case a participant feels distressed and wants to
quickly close the interface, or if the interface is
being accessed in a public setting and a participant
does not want others to know about their usage.
9. Topic guides of interviews with the internal pilot,
intervention and low-engagement groups will con-
sider safety issues, and analysis of interviews allows
the opportunity to refine the NEON Intervention or
trial processes in light of unanticipated safety issues.
Our decision to use content warnings (also known as
trigger warnings) has drawn on a review of the literature
on content warnings, conducted through systematic
searches of the MEDLINE, Cumulative Index to Nursing
and Allied Health (CINAHL) and PsycINFO databases.
These have identified four publications presenting
empirical evidence on the impact of real-world usage of
content warnings. These studies show that content
warnings can reduce harm by reducing stress in students
with post-traumatic stress disorder (PTSD) diagnoses
[122] and by reducing negative emotions produced by
engaging material [123]. They can be useful if provided
well in advance of discussions in an educational context
[124] and can reduce negative emotions and signal sup-
portive environments, which may promote engagement
with otherwise distressing material in the long run [123].
They can however also increase avoidance, which may
prevent people from learning to cope with distressing
content [123]. Only one RCT has been conducted exam-
ining the psychological effects of issuing content warn-
ings [125]. This trial found that warnings produced a
small increase in self-reported anxiety after reading po-
tentially disturbing literary passages amongst people
who believed words can cause harm. It also found a
slightly increased perceived risk of suffering long-term
emotional harm in the wake of a traumatic event.
Safety of narrative donors
The NEON Intervention presents recovery narratives from
the NEON Collection. A protocol for the management of
the NEON Collection was previously approved by the UK
Health Research Authority (HRA). The IRAS ID for this
approval is 24734. The protocol was given favourable
opinion by the West London & Gene Therapy Advisory
Committee (GTAC) Research Ethics Committee. The REC
reference is 18/LO/0991. This approved protocol supports
the safety of individuals whose narratives are incorporated in
the NEON Collection in the following ways:
 Narratives are only included in the NEON Collection
where valid consent has been documented. Narratives
sourced from public collections are only included if
the narrator has provided his/her publisher with
consent for public reuse, or if the narrator has been
approached and provided explicit consent for use in
the NEON Collection. Where a narrative is donated
directly to the NEON Collection, informed consent is
provided through an online consent form. Narrators
can withdraw consent for inclusion whilst the NEON
Collection is in use.
 Narratives are incorporated exactly as originally
published.
 All candidate narratives are assessed by at least one
researcher against inclusion and exclusion criteria
published at http://researchintorecovery.com/
neoncollection. If eligibility is unclear, a final decision
is made by a Collection Steering Group consisting of
four members of the LEAP and two researchers.
 Third parties can request withdrawal of a narrative,
e.g. if a narrator has died, or if they assert that the
narrator did not have capacity to consent to
inclusion of their narrative. They do not have an
automatic right to withdrawal, in order to protect
the rights of the narrator to have their story told. A
final decision on third-party requests is made by the
Collection Steering Group.
These strategies were developed with advice from the
LEAP. Three members of this panel have published their
own recovery narratives.
Trial status
The current version of the trial protocol is v4.0, dated
16 January 2020.
The trial opened to recruitment on 9 March 2020.
Planned recruitment close is 30 April 2021. Planned trial
end is 30 April 2022.
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